Medifirst Solutions 10-Q 20 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 20, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Medifirst Solutions, Inc.
Entity Central Index Key	0001522704
Trading Symbol	MFST
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		9,050,333

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 275,705	$ 83,387
Accounts receivable	4,300
Inventory	31,163	32,677
Total current assets	311,168	116,064
Property, Plant and Equipment, net	432	592
Operating lease right of use asset, net	36,959
Other Assets
Security Deposit	650	650
Intangible Asset - License Agreement, net	97,501	101,252
Total other assets	135,110	101,902
Total Assets	446,710	218,558
Liabilities
Accounts payable and accrued expenses	200,414	221,770
Accrued expenses - officer's compensation	403,186	388,981
Due to related party	8,921	8,921
Loans payable - stockholders	6,375	8,375
Note Payable for license agreement
Convertible notes payable	588,092	522,446
Convertible notes payable - related party	41,505	51,005
Derivative Liabilities	946,703	263,468
Operating lease obligation - current portion	15,724
Total current liabilities	2,210,919	1,464,966
Operating lease obligation, net of current portion	21,818
Total liabilities	2,232,737	1,464,966
Commitments & Contingencies (Note 8)
Stockholders' Equity:
Common stock, $0.0001 par value; 4,000,000,000 shares authorized, 5,808,883 and 3,482,840 shares issued and outstanding, respectively	580	348
Additional paid in capital	3,755,408	3,486,856
Accumulated deficit	(5,542,067)	(4,733,663)
Total Stockholders' Equity	(1,786,028)	(1,246,408)
Total Liabilities & Stockholders' Equity	446,710	218,558
Series A Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	50	50
Series B Preferred Stock [Member]
Stockholders' Equity:
Preferred stock	1	1
Series C Preferred Stock [Member]
Stockholders' Equity:
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	4,000,000,000	4,000,000,000
Common stock, shares issued	5,808,883	3,482,840
Common stock, shares outstanding	5,808,883	3,482,840
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	8,000	8,000
Preferred stock, shares outstanding	8,000	8,000
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	315	177
Preferred stock, shares outstanding	315	177

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Product sales, net	$ 17,900	$ 4,550
Consulting Income	8,500
Total Revenues	26,400	4,550
Cost of goods sold	1,515	379
Gross income	24,885	4,171
Expenses:
Officer's compensation	37,500	37,500
Advertising and promotion	671	789
Computer and internet	479	150
Consulting fees	205,515	38,100
Professional fees	8,202	36,315
Rent		5,822
Operating lease	3,188
Travel	486	870
Dues and subscriptions	866	269
Other	18,820	21,279
Total operating expenses	275,727	141,094
Net loss from Operations before other income, expenses	(250,842)	(136,923)
Other income and (expense)
Interest expense	(130,998)	(134,703)
Interest income	1
Gain on extinguishment of debt	10,561
Change in fair value -derivatives	(437,126)	(22,943)
Net loss before provision for income tax	(808,404)	(294,569)
Provision for income taxes
Net Loss	$ (808,404)	$ (294,569)
Loss per common share - Basic and fully diluted	$ (0.17)	$ (0.28)
Weighted average number of shares outstanding - Basic and fully diluted	4,775,553	1,066,708

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Deficit	Preferred Class A	Preferred Class B	Preferred Class C	Total
Balance at Dec. 31, 2017	$ 85	$ 2,831,163	$ (3,665,129)	$ 50	$ 1		$ (833,830)
Balance, Shares at Dec. 31, 2017	849,437			500,000	8,000
Issuance of common shares upon conversions of notes payable	$ 38	41,635					41,673
Issuance of common shares upon conversions of notes payable, Shares	376,111
Issuance of common shares for services rendered	$ 2	7,200					7,202
Issuance of common shares for services rendered, Shares	18,000
Adjustment for reverse stock split taken place in 2018		124,232					124,232
Additional paid in capital from derivative liability on debt conversion		77,117					77,117
Net Loss			(294,569)				(294,569)
Balance at Mar. 31, 2018	$ 125	3,081,347	(3,959,698)	$ 50	$ 1		(878,175)
Balance, Shares at Mar. 31, 2018	1,243,548			500,000	8,000
Issuance of common shares upon conversions of notes payable	$ 9	9,089					9,098
Issuance of common shares upon conversions of notes payable, Shares	92,015
Issuance of common shares for services rendered	$ 7	20,252					20,259
Issuance of common shares for services rendered, Shares	67,500
Adjustment for reverse stock split taken place in 2018		15,934					15,934
Additional paid in capital from derivative liability on debt conversion		36,043					36,043
Net Loss			(436,327)				(436,327)
Balance at Jun. 30, 2018	$ 141	3,162,665	(4,396,025)	$ 50	$ 1		(1,233,168)
Balance, Shares at Jun. 30, 2018	1,403,063			500,000	8,000
Issuance of common shares upon conversions of notes payable	$ 42	11,646					11,688
Issuance of common shares upon conversions of notes payable, Shares	427,755
Issuance of common shares for services rendered	$ 63	46,070					46,133
Issuance of common shares for services rendered, Shares	634,053
Issuance of preferred shares for services rendered
Additional paid in capital from derivative liability on debt conversion		10,441					10,441
Net Loss			(40,112)				(40,112)
Balance at Sep. 30, 2018	$ 246	3,230,822	(4,436,137)	$ 50	$ 1		(1,205,018)
Balance, Shares at Sep. 30, 2018	2,464,871			500,000	8,000
Issuance of common shares upon conversions of notes payable	$ 102	22,635					22,737
Issuance of common shares upon conversions of notes payable, Shares	1,017,959
Issuance of common shares for services rendered
Issuance of preferred shares for services rendered		204,182					204,182
Issuance of preferred shares for services rendered, Shares						177
Additional paid in capital from derivative liability on debt conversion		29,218					29,218
Net Loss			(297,526)
Balance at Dec. 31, 2018	$ 348	3,486,856	(4,733,663)	$ 50	$ 1		(1,246,408)
Balance, Shares at Dec. 31, 2018	3,482,830			500,000	8,000	177
Issuance of common shares upon conversions of notes payable	$ 205	36,810					37,015
Issuance of common shares upon conversions of notes payable, Shares	2,049,043
Issuance of common shares for services rendered	$ 28	14,099					14,127
Issuance of common shares for services rendered, Shares	277,000
Issuance of preferred shares for services rendered		184,507					184,507
Issuance of preferred shares for services rendered, Shares						138
Additional paid in capital from derivative liability on debt conversion		33,135					33,135
Net Loss			(808,404)				(808,404)
Balance at Mar. 31, 2019	$ 581	$ 3,755,408	$ (5,542,067)	$ 50	$ 1		$ (1,786,028)
Balance, Shares at Mar. 31, 2019	5,808,873			500,000	8,000	315

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (808,404)	$ (294,569)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation & amortization expense	3,910	3,910
Gain on debt settlement	(10,561)
Stock Based Compensation	198,634	9,000
Change in assets and liabilities
Accounts receivable	(4,300)
Accounts payable and accrued expenses	(7,156)	15,956
Change in fair value - derivatives	437,126	22,943
Amortization of debt discount & other financing costs	94,172	117,285
Related party and stockholder's loan	(2,000)	(406)
Prepaid expenses		(6,200)
Change in operating lease right of use asset	(36,959)
Change in operating lease obligation	37,542
Inventory	1,514	379
Net cash used by operating activities	(96,482)	(131,702)
Cash flows from investing activities:
Net cash used by investing activities
Cash flows from financing activities:
Principal payments on debt	(5,700)
Proceeds from sale of Convertible notes payable	294,500	78,750
Net cash provided by financing activities	288,800	78,750
Net increase (decrease) in cash	192,318	(52,952)
Cash at beginning of period	83,387	287,569
Cash at end of period	275,705	234,617
Cash paid during the period for:
Income taxes	500	135
Non-cash investing and financing activities:
Common stock issued for convertible debt-related party	3,800	15,000
Derivative liability extinguished upon conversion	33,135	77,117
Common stock issued for convertible debt with derivatives	33,215	64,245
New discounts associated with derivatives on convertible debt	$ 241,691

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Medifirst Solutions, Inc. ("MSI" or the "Company") was incorporated in Nevada in November 2010. The Company has not generated significant sales to date. The Company intends to have a diverse product line of consumer products. Since inception, the Company has been engaged in business planning activities, including researching the industry, identifying target markets for the Company's products, developing the Company's models and financial forecasts, performing due diligence regarding potential geographic locations most suitable for establishing the Company's offices and identifying future sources of capital. At the present time, the Company is building products and affiliations in and related to the cosmetic healthcare industry. The company has started to hire a salesforce and sign distribution agreements in anticipation of future sales. In July 2016, Medifirst, in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.The Company is actively putting together a sales and distribution team to offer our lasers in the US and foreign markets. Pursuant to a sale and purchase agreement dated August 19, 2015 between the Company and the Company's president, the Company acquired 100% of the equity interests in Medical Lasers Manufacturer, Inc. ("MLM") with the total purchase price of 20,000 shares of the Company's common stock at $0.001 per share (or $20). The fair value of the acquired entity was $20. The transaction was considered as a business acquisition and accordingly the acquisition method of accounting has been applied. MLM had no assets at the date of the business combination. On April 18, 2018, the Company incorporated Concierge Concepts Rx (CCRx), in the State of New Jersey, to be an 80% majority-owned subsidiary. In consideration for his contribution of know-how, CCRx's co-founder, Walter Molokie, CCRx has agreed to issue a 20% minority interest in CCRx to Mr. Molokie and/or his designees.On July 1, 2018 the Company acquired 100% of the equity interest in Concierge Concepts Rx, Inc. ("CCRx") with the total purchase price of $20. The fair value of the acquired entity was $20 since the entity was just recently formed and had no identifiable assets or liabilities. The $20 cash payment is for the purchase of CCRx common stock upon acquisition. Medifirst launched Concierge Concepts Rx, a new division focused on the pharmaceutical industry.CCRx that provides unique specialty drug consulting and niche billing services to independent pharmacies and retail pharmacy chains. This division commenced operations in the quarter ended September 30, 2018 with limited activity and is included in the accompanying consolidated financial statements. The Consolidated financial statements include the accounts of MSI and its wholly owned subsidiaries, MLM and CCRx. All material intercompany balances and transactions have been eliminated in consolidation. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's current technology. Basis of Presentation The unaudited interim consolidated financial statements include the accounts of Medifirst Solutions Inc. and its wholly owned subsidiary (Medical Laser Manufactures, Inc., and Concierge Concepts Rx (CCRx) (collectively referred to as the "Company"). All material intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the consolidated financial position of the Company as of March 31, 2019, the consolidated results of its operations for the three-month periods ended March 31, 2019 and 2018, the consolidated change in stockholders' equity for the three-month period ended March 31, 2019 and 2018 and the consolidated cash flows for the three-month periods ended March 31, 2017 and 2018. The results of operations for the three-month period ended March 31, 2019 are not necessarily indicative of the operating results for the full year. These financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures for the year ended December 31, 2018 included in the Company's Annual Report on Form 10-K for the year then ended. Some items in the prior year financial statements were reclassified to conform to the current presentation. Reclassifications had no effect on prior year net income or shareholders' equity. Effective July 23, 2018, the Company effected a 1-for-1,000 reverse stock split of its issued and outstanding common stock. The number of shares of common stock issued and outstanding post- reverse stock split is 1,404,073. All fractional shares have been rounded up to the next whole share. There is no reduction in the number of the Company's shareholders of record. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse stock split as if such reverse stock split occurred on the first day of the first period presented. Revenue Recognition The Company also derives consulting revenue from it's CCRx division. Such revenue is recognized at the time services are performed. The Company adopted the new accounting standard on revenue recognition, ASU No. 2014-09 (Topic 606) "Revenue from Contracts with Customers", which became effective on January 1, 2018. Since the Company was classified as an Emerging Growth Company under SEC rules, ASC 606 was not adopted until January 1, 2019. Revenue is recognized at the time the product is delivered or services are performed. Provision for sales returns are estimated based on the Company's historical return experience. Revenue is presented net of returns. The Company's revenue recognition policy standards include the following elements under ASU No. 2014-09 (Topic 606): i. Identify the contract with a customer. In general, the contract with the customer is usually a purchase order for the sales of laser devices. For consulting work, there is a written contract with the customer and a statement of work. ii. Identify the performance obligations in the contract. The performance obligation under the laser sales contract is the shipment and delivery of the product to the customer. The performance obligations under consulting contracts is the successful performance of the consulting work detailed in the statement of work iii. Determine the transaction price. The transaction price is negotiated by the customer and the Company's sales team and/or CEO for laser sales. For consulting work, the price is determined based upon hours and commitment of time devoted by the consultants. iv. Allocate the transaction price to the performance obligations in the contract. The transaction price is allocated to the performance obligation of the delivery of the laser product. The transaction price is allocated to the amounts contracted in the consulting agreements for consulting revenue. v. Recognize revenue when (or as) the entity satisfies a performance obligation. Upon shipment (FOB) and delivery (FOB destination) of laser products, revenue is recognized. Upon completion of statement of work in the consulting contracts revenue is recognized. Accounts Receivable The Company extends credit to its customers in the normal course of business and performs ongoing credit evaluations of its customers, maintaining an allowance for potential credit losses. Accounts receivable is reported net of the allowance for doubtful accounts. The allowance is based on management's estimate of the amount of receivables that will actually be collected. The Company has not recorded an allowance for doubtful accounts as of March 31, 2019 or December 31, 2018. Inventory Inventory consists of finished goods and is stated at the lower of cost (first-in, first-out) or market value. Finished goods inventory includes hand held laser devices, their carrying cases and goggles. Equipment Equipment, consisting of computer equipment, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, of five years. Long-Lived Assets The Company reviews long-lived assets, such as equipment, for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds the estimated future cash flows, an impairment loss will be recorded by the amount the carrying value exceeds the fair value of the asset. Intangible Asset- Licensing Agreement On March 8th 2016 (with an effective date of October 1, 2015), the company, through it's sole wholly-owned subsidiary ("Licensee"), entered into a Product and Know-How License Agreement ("Agreement") with a Florida Corporation ("Licensor") which is owned by a related party - the son of the Company's CEO. The license provides with respect to the Technology, Licensor hereby grants to Licensee an irrevocable, nontransferable, royalty-bearing license, with a right of sublicense (the "License"), throughout the Territory in the Field of Use, whether or not under the Licensed Patent, to: - use or submit or deliver the Technology and/or any Product to any regulatory body throughout the Territory for purposes of obtaining approval to make, Sell, offer for Sale, import, export and distribute the Technology or Products; and - use or copy the Technology and/or any Product; and - market, make, have made, Sell, offer for Sale, import and distribute Products; and - sublicense the Technology; and - prepare, or have prepared on its behalf, modifications, enhancements and/or derivative works of the Technology. In connection with the license granted, Licensor hereby grants to Licensee a license to the Licensed Patents, whether now existing or hereafter acquired. The consideration for the licensing agreement consisted of the issuance of 25,000 Series B Preferred stock shares to the Licensor (at par) plus a $150,000 promissory note issued by the Company to the licensor. On September 15, 2017 the Note was amended to include provisions to allow conversion of the Note into common stock of the Company. On September 25, 2017, $16,250 in principal on this note was satisfied by the conversion into 25,000,000 shares of the Company's common stock. During the quarter ended June 30, 2018, the original noteholder assigned $20,000 in principal to an unrelated third-party. There were $32,550 in cash principal paydowns to the original noteholder during the year ended December 31, 2018. There were an additional $33,345 in conversions to common stock that took place on these two notes during the year ended December 31, 2018. During the quarter-ended March 31, 2019 there were $5,700 in principal paydowns to the original noteholder and $3,800 in conversions to common stock. The principal balance on this note as of March 31, 2019 is $41,505 to the original noteholder and $16,650 in principal balance to the new unrelated third-party noteholder. The last part of the consideration in this license agreement is the royalty payments which have not taken effect yet since they are based on sales for which the company has had only minimum thus far. The licensing agreement is for a ten-year period effective from October 1, 2015. The cost of the licensing agreement is being amortized over its ten-year period and charged to income on a straight-line basis. Product Warranty We generally provide a one-year warranty on our products. Currently no material evaluations or studies have been performed to obtain warranty data since there are so few sold products outstanding. As sales increase, the Company will estimate future warranty costs from historical data and trends of product reliability and costs of repairing and replacing defective products. Debt Issue Costs and Debt Discount The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of convertible debt. These costs are amortized over the life of the debt to interest expense. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts are immediately expensed. Beginning in 2015, the Company adopted ASU 2015-03: Simplifying the Presentation of Debt Issuance Costs and has reflected the deferred financing costs as a direct reduction of the related debt (See table included in Note 5 to Consolidated Financial Statements). Original Issue Discount For certain convertible debt issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded to debt discount, reducing the face amount of the note and is amortized to interest expense over the life of the debt. Derivative Liabilities Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. The Company assessed its securities for purposes of determining the proper accounting treatment and valuation as set forth in the Statement of Financial Accounting Standard ASC 820–10–35–37 Fair Value in Financial Instruments Accounting for Derivative Instruments and Hedging Activities In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once the derivative liabilities are determined, they are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the condensed consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments The carrying amounts reported in the balance sheets for cash, accounts receivable, accounts payable, and other accrued liabilities approximate their fair values. Segment Information The Company follows Accounting Standards Codification ("ASC") 280, "Segment Reporting". The Company currently operates in a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Net Income (Loss) Per Common Share The Company calculates net income (loss) per share based on the authoritative guidance. Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which the Company incurs losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive. As described in Note 5 to the financial statements, as of March 31, 2019, convertible debt can be converted into approximately 49,753,279 shares of common stock. Income Taxes The Company utilizes the accrual method of accounting for income taxes. Under the accrual method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and the tax basis of the assets and liabilities, and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recognized, when it is more likely than not, that such tax benefits will not be realized. The Company recognizes the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount recognized in the financial statements is the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. The Company did not have any unrecognized tax benefits as of March 31, 2019, and does not expect this to change significantly over the next 12 months. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with ASC 718, Compensation - Stock Compensation. ASC 718 requires all share-based compensation payments to be recognized in the financial statements based on the fair value on the issuance date. The Company adopted the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 did not have any impact on the Company's financial statement presentation or disclosures. The Company did not have any equity instruments that required revaluation under this new standard. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At December 31, 2018 and March 31, 2019, the Company had $83,382 and $275,705 in cash equivalents respectively. Recent Pronouncements The Company is no longer an "emerging growth company" as defined in Section 2(a)(19) of the Securities Act. In August 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-15, "Intangibles-Goodwill and Other-Internal-Use Software (Topic 350): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract", which align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). ASU 2018-15 is effective for the Company beginning in the first fiscal quarter of 2022, with early adoption permitted. The Company is currently evaluating the impact of this ASU on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments," which amends the guidance on measuring credit losses on financial assets held at amortized cost. The amendment is intended to address the issue that the previous "incurred loss" methodology was restrictive for an entity's ability to record credit losses based on not yet meeting the "probable" threshold. The new language will require these assets to be valued at amortized cost presented at the net amount expected to be collected with a valuation provision. This update standard is effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this ASU on the consolidated financial statements. In August 2018, the Securities and Exchange Commission (the "SEC") issued a final rule that amends certain of the SEC's disclosure requirements, including requirements relating to disclosures about changes in stockholders' equity. For Quarterly Reports on Form 10-Q, the final rule extends to interim periods the annual requirement in Rule 3-04 of Regulation S-X, to disclose (1) changes in stockholders' equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders' equity, in the form of a reconciliation, for "the current and comparative year-to-date [interim] periods, with subtotals for each interim period," i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 of Regulation S-X permits the disclosure of changes in stockholders' equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. SEC staff has indicated it would not object if a registrant's first presentation of the changes in shareholders' equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company conformed to this rule in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.

Property, Plant and Equipment (

Property, Plant and Equipment (Net)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT (NET)	Note 2. PROPERTY, PLANT AND EQUIPMENT (NET) Equipment is recorded at cost and consisted of the following at March 31, 2019 and December 31, 2018: March 31, December 31, Computer equipment $ 8,956 $ 8,956 Less: accumulated depreciation (8,525 ) (8,365 ) $ 432 $ 592 Depreciation expense was $159 and $159, for the quarters ended March 31, 2019 and 2018 respectively.

Due to Related Party

Due to Related Party	3 Months Ended
	Mar. 31, 2019
Due to Related Party [Abstract]
DUE TO RELATED PARTY	Note 3. DUE TO RELATED PARTY The Company was indebted to a related party through common management in the amount of $8,921 at March 31, 2019 and December 31, 2018, respectively. The loan bears no interest and is payable on demand. See Note 10 for additional related party transactions.

Loans Payable - Stockholders

Loans Payable - Stockholders	3 Months Ended
	Mar. 31, 2019
Loans Payable - Stockholders [Abstract]
LOANS PAYABLE - STOCKHOLDERS	Note 4. LOANS PAYABLE - STOCKHOLDERS During the quarter ended March 31, 2019 and the year ended December 31, 2018 a stockholder of the Company advanced the Company $-0- and $-0- respectively. The loan has a balance of $6,375 at March 31, 2019 and $8,375 at December 31, 2018, respectively. The loan bears no interest and is payable on demand. In December 2012, the Company issued a promissory note to a stockholder in the amount of $5,000 with interest at 10% per annum. Principal and interest were due and payable on June 2, 2013. In April 2014, the note was amended to provide the note holder with the option to convert the note to the Company’s common stock at $0.0001 per share. Subsequently, in 2014, in a private transaction, the note holder transferred $2,500 of note principal to third parties and the new holders converted their holdings into 2,500 shares of the Company’s common stock. During 2015, the original note holder transferred an additional $2,400 of note principal to third parties who converted their holdings into 2,400 shares of the Company’s common stock. At March 31, 2019 and December 31, 2018, the loan balance was $100 and $100, respectively. At March 31, 2019 and December 31, 2018, the Company was indebted to a stockholder in the amount of $1,000 and $1,000, respectively. The loan has an interest rate of 26.7%. Principal and accrued interest were due and payable on January 1, 2014.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	Note 5. CONVERTIBLE NOTES PAYABLE Note Payable-BS In March 2011, the Company issued $800 aggregate principal amount of 6% convertible notes due in January 2012. Interest on the notes accrue at the rate of 6% per annum and are payable when the notes mature. The notes matured prior to conversion but have not been repaid. Interest continues to accrue at the rate of 6% per annum. The holder of one of the notes converted $110 of note principal into 1,100 shares of common stock as follows: Date of Conversion Principal Conversion Shares June 2013 $ 70 $ 0.0001 700 August 2013 $ 40 $ 0.0001 400 In August 2013, in a private transaction, the same note holder transferred $330 of the remaining note principal plus $55 in accrued interest to a third party. In August 2013, in a private transaction, the new note holder transferred $5 of the remaining note principal to a third party who then converted the note into 50 shares of common stock. In September 2013, the new note holder converted $100 of note principal into 1,000 shares of common stock. In September 2013, in a private transaction, the new note holder transferred $35 of the remaining note principal to a third party who then converted the note into 350 shares of common stock. In November and December 2013, the new note holder converted an additional $90 of note principal into 900,000 shares of common stock as follows: Date of Conversion Principal Conversion Shares November 2013 $ 40 $ 0.0001 400 December 2013 $ 50 $ 0.0001 500 In March and April 2014, the new note holder converted an additional $90 of note principal into 900,000 shares of common stock as follows: Date of Conversion Principal Conversion Shares March 2014 $ 50 $ 0.0001 500 April 2014 $ 40 $ 0.0001 400 Subsequent to these conversions there remains $125 in note principal outstanding at March 31, 2019. Note Payable-SF In July 2013, the holder of the second note converted $240 of note principal into 400 shares of the Company’s common stock at $0.0006 per share. At March 31, 2019 and December 31, 2018, the note had a remaining principal balance of $60 and $60, respectively. At any time on or after the maturity date, the holders of the notes, have the option of converting any of the unpaid principal and interest into the Company’s common stock. The notes plus any accrued but unpaid interest are convertible at the rate of $0.0001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 580,307 shares at March 31, 2019 and 347,936 shares at December 31, 2018. Note Payable-RK In May 2012, the Company issued a $25,000 6% per annum note that matured in November 2012. In December 2012 the note was amended to be a convertible note. Interest on the note accrues interest at 6% per annum and is payable when the note matures. The holder of the $25,000 note had the option of converting it at any time prior to maturity. The note plus any accrued but unpaid interest were convertible at the rate of $0.001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock. The holder of the note converted $1,010 of note principal into 1,010 shares of common stock as follows: Date of Conversion Principal Conversion Shares December 2012 $ 150 $ 0.001 150 January 2013 $ 660 $ 0.001 660 March 2013 $ 200 $ 0.001 200 In July 2013, the Company retired $14,000 of note principal in payment for consulting services provided to the note holder. In July 2013, the note holder converted $300 of note principal into 300 shares of the Company’s common stock. In July 2013, in a private transaction, the note holder transferred the remaining note principal balance of $9,690 to a third party (See Note Payable-NW Note Payable-NW After receiving the transfer of the principal balance of $9,690 in July 2013 in the private transaction noted in Note Payable-RK In October 2013, the note holder converted $400 of note principal into 400 shares of the Company’s common stock at $0.001 per share. In October 2014, the note holder converted $1,100 of note principal into 1,100 of the Company’s common stock. The note holder has the option of converting the balance at any time with the approval of the Board of Directors. The note plus any accrued but unpaid interest are convertible at the rate of $0.001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 347,936 shares at December 31, 2018 and 49,753,279 shares at March 31, 2019. In August 2016, the note holder converted $3,000 of note principal into 3,000,000 shares of the Company’s common stock. At March 31, 2019 and December 31, 2018, the remaining principal balance on this portion of the note is $715 and $715 respectively. Note Payable-MC #2 In April 2015, the Company issued a $3,000 8% per annum note that matures in October 2015. The holder of the note has the right to convert the principal into shares of the Company’s common stock at any time 180 days after the closing date at $0.0001 per share. Interest on the note accrues interest at 8% per annum and is payable when the note matures. During January 2017, the current noteholder converted $1,100 in principal balance into 11,000 shares of common stock. During the same period, the current noteholder transferred $600 of the remaining principal balance to another investor who then converted the entire principal balance he received into 6,000 shares of common stock. During April 2017, the current noteholder converted $410 of remaining principal into 6,000 shares of common stock. There remains $890 in principal balance at March 31, 2019 and at December 31, 2018. Convertible Notes Payable-SO (8%) On May 2, 2016, the Company issued to an Investor a convertible redeemable note in the principal amount of $57,750 (“the Note”). The Note, which matures on May 2, 2017, pays interest at the rate of 8% per annum. The note contains a 10% original issue discount. The holder of the note is entitled, at its option beginning on the 6 month anniversary, to convert all or any of the principal face amount of the Note then outstanding into shares of the Company’s common stock at the price equal to 55% of the lowest trading price for the twenty prior trading days including the date of conversion. During the quarter ended March 31, 2017 the noteholder converted $32,298 of the principle balance into 23,490 shares of common stock thereby leaving a principal balance of $25,452 on the note at December 31, 2017. During the first quarter of 2018, the noteholder converted $23,000 of the principle balance into 122,727 shares of common stock thereby leaving a principal balance of $2,452 on the note at June 30, 2018. During the quarter ended September 30, 2018, the noteholder converted the remaining balance of the note into 148,316 shares on common leaving no balance due on the note as of December 31, 2018. There is $12,896 in accrued interest and penalty assessments on this note as of December 31, 2018 which is included in accrued expenses payable on the balance sheet. During the quarter-ended March 31, 2019 the Company reached a settlement agreement with the noteholder where it paid in cash or through conversion all the outstanding interest and penalty and nothing is due to the noteholder as of March 31, 2019. The noteholder converted $5,813 of interest and penalty into 398,859 shares of common stock of the Company and $9,815 was paid in cash to the noteholder by the Company thereby resulting in a recognized loss on the extinguishment of the debt in the amount of $2,732. Convertible Notes Payable - Funding (8%) On May 1, 2017, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”) for the sale of convertible redeemable notes in aggregate principal amount of $1,012,500. The back end-notes were all cancelled so only a total of $506,250 were actually funded. On May 1st, 2017 and June 2, 2017, the Company and the Investor conducted the first two closings under the Purchase Agreement, pursuant to which the Company issued to the Investor (i) a convertible redeemable note in principal amount of $131,250 (the “$131K Note”); and (ii) a convertible redeemable note in principal amount of $125,000 (the “$125K Note”). On July 10, 2017 and August 7, 2017, the Company and the Investor conducted the second two closings under the Purchase Agreement, pursuant to which the Company issued to the Investor two convertible redeemable notes each in the principal amount of $125,000; The two notes issued May 1, 2017 ($131,250) and June 2, 2017 ($125,000) became convertible on October 28, 2017 and December 4, 2017 respectively and required derivative treatment at that time. The embedded derivative was bifurcated and accounted for separately along with the derivative discount. The derivative liability is marked-to-market each quarter with the resulting gain or loss valuation being reported in the statement of operations. During the quarter ended December 31, 2017 (after the six-month waiting period) the holder of the original note in the principal amount of $131,250 converted $21,500 and $15,350 of the note’s principal balance into 35,058 and 39,714 shares of the Company’s common stock, respectively. The principal balance remaining on this convertible note is $94,400 as of December 31,2017. During the quarter ended March 31, 2018 the holder of the original note converted, through four separate conversion transactions, a total of $38,870 of the note’s principal balance into total of 193,384 shares of the Company’s common stock. During the quarter ended June 30, 2018 the holder of the original note converted $10,030 of the note’s principal balance into total of 62,015 shares of the Company’s common stock. During the quarter ended September 30, 2018 the holder of the original note converted $2,200 of the note’s principal balance into total of 69,439 shares of the Company’s common stock. During the quarter ended December 31, 2018 the holder of the original note converted $10,640 of the note’s principal balance and $1,312 of accrued interest into total of 148,545 shares of the Company’s common stock. During the quarter-ended March 31, 2019 the noteholder converted $21,125 in principal and $2,977 in accrued interest into 1,249,684 shares of common stock. The principal balance remaining on this convertible note is $11,535 as of March 31, 2019. Convertible Notes Payable - JR (5%) On August 2, 2017 the Company issued a convertible note payable (promissory note) to an investor in the principal amount of $50,000. The note matures on August 2, 2018 and bears interest at 5%. The note holder has the right at any time on or after the day that is six months from August 2, 2018 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock at a fixed price of .003 per share. The embedded derivative on the note was valued and bifurcated effective October 1, 2018. During the quarter ended December 31, 2018, $4,500 in principal on this note was satisfied by the noteholder converting such amount into 150,000 shares of the Company’s common stock. During the quarter-ended March 31, 2019 the noteholder converted $3,300 in principal balance into 200,000 shares of the Company’s common stock. The remaining principal balance outstanding on the note is $42,200 as of March 31, 2019. Convertible Notes Payable - MLM (10%) As more fully described in Note 1 to the financial statements, on March 8th 2016 (with an effective date of October 1, 2015), the company, through it’s sole wholly-owned subsidiary (“Licensee”), entered into a Product and Know-How License Agreement (“Agreement”) with a Florida Corporation (“Licensor”) which is owned by a related party - the son of the Company’s CEO. The consideration for the licensing agreement consisted of the issuance of 25,000 Series B Preferred stock shares to the Licensor (at par) plus a $150,000 promissory note issued by the Company to the licensor. During the quarter-ended June 30, 2017, $18,986 in accrued interest was satisfied through the issuance of 17,273 shares of the Company’s common stock. On September 15, 2017 the Note was amended to include provisions to allow conversion of the Note into common stock of the Company. At such time the Note was valued with it’s embedded derivative and discount. On September 25, 2017, $16,250 in principal on this note was satisfied by the conversion into 25,000 shares of the Company’s common stock leaving a balance on the note of $133,750 at December 31, 2017. During the year ended December 31, 2018 the Company made cash paydowns to the noteholder in the total amount of $32,550. In addition, $30,195 in principal balance on the note was converted into 495,000 shares of the Company’s common stock. The ending principal balance on this note at December 31, 2018 is $51,005 to the original noteholder. During the year-ended December 31, 2018 the unrelated third-party noteholder converted $3,350 in principal balance into 120,000 shares of the Company’s common stock thereby leaving a principal balance to this unrelated noteholder in the amount of $16,650. During the quarter-ended March 31, 2019 the Company made principal paydowns in the amount of $5,700 to the original noteholder and the original noteholder converted $3,800 in principal balance into 200,000 shares of the Company’s common stock. The ending principal balance on this note at March 31, 2019 is $41,505 to the original noteholder and $16,650 to the unrelated third-party noteholder. Convertible Notes Payable - LG (8%) (Notes 5 & 6) On January 25, 2018 the Company issued a convertible note payable (promissory note) to an investor in the principal amount of $78,750. The note matures on January 25, 2019 and bears interest at 8%. The note holder has the right at any time on or after the day that is six months from January 25, 2018 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $78,750 is outstanding as of March 31, 2019. On June 4, 2018 the Company issued a convertible note payable (promissory note) to an investor in the principal amount of $52,500. The note matures on June 4, 2019 and bears interest at 8%. The note holder has the right at any time on or after the day that is six months from June 4, 2018 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $52,500 is outstanding as of March 31, 2019. Convertible Notes Payable - PULG (8%) (Notes 1 & 2) On October 1, 2018 the Company issued a convertible note payable (convertible promissory note PULG (8%) Note 1) to an investor in the principal amount of $58,000. The note matures on April 1, 2020 and bears interest at 8%. The note holder has the right at any time on or after the day that is six months from October 1, 2018 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $58,000 is outstanding as of March 31, 2019. On November 19, 2018 the Company issued a convertible note payable (convertible promissory note PULG (8%) Note 2) to an investor in the principal amount of $65,000. The note matures on May 19, 2020 and bears interest at 8%. The note holder has the right at any time on or after the day that is six months from November 19, 2018 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $65,000 is outstanding as of March 31, 2019. Convertible Notes Payable - PULG (8%) (Notes 3, 4 & 5) On January 24, 2019 the Company issued a convertible note payable (convertible promissory note PULG (12%) Note 3) to an investor in the principal amount of $43,000. The note matures on May 24, 2020 and bears interest at 12%. The note holder has the right at any time on or after the day that is six months from January 24, 2019 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $43,000 is outstanding as of March 31, 2019. On February 4, 2019 the Company issued a convertible note payable (convertible promissory note PULG (12%) Note 4) to an investor in the principal amount of $38,000. The note matures on November 30, 2019 and bears interest at 12%. The note holder has the right at any time on or after the day that is six months from February 4, 2019, 2018 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $38,000 is outstanding as of March 31, 2019. On March 26, 2019 the Company issued a convertible note payable (convertible promissory note PULG (8%) Note 5) to an investor in the principal amount of $43,000. The note matures on September 21, 2020 and bears interest at 8%. The note holder has the right at any time on or after the day that is six months from March 26, 2019 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $43,000 is outstanding as of March 31, 2019. Convertible Notes Payable - BR (12%) (Note 1) On February 25, 2019 the Company issued a convertible note payable (convertible promissory note BR (12%) Note 1) to an investor in the principal amount of $65,000. The note matures on February 25, 2020 and bears interest at 12%. The note holder has the right at any time on or after the day that is six months from February 25, 2019 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $65,000 is outstanding as of March 31, 2019. Convertible Notes Payable - CB (8%) (Note 1) On February 27, 2019 the Company issued a convertible note payable (convertible promissory note CB (8%) Note 2) to an investor in the principal amount of $51,500. The note matures on August 20, 2020 and bears interest at 8%. The note holder has the right at any time on or after the day that is six months from February 27, 2019 to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $51,500 is outstanding as of March 31, 2019. Convertible Notes Payable - GS (8%) (Note 1) On February 20, 2019 the Company issued a convertible note payable (convertible promissory note GS (8%) Note 1) to an investor in the principal amount of $54,000. The note matures on August 20, 2020 and bears interest at 8%. The note holder has the right at any time after issuance to convert any part or all of the outstanding unpaid principal balance into shares of the Company’s common stock. The entire principal balance of $54,000 is outstanding as of March 31, 2019. The Company’s convertible notes payable and the related derivative liabilities, derivative discount, deferred financing costs and original-issue discount are presented in the financial statements at March 31, 2019 as follows: 3/31/2019 Remaining Original Deferred Total Principal Issue Derivative Financing Convertible Derivative Debt Amount Discount Discount Costs Notes Payable Liability Note Payable - BS $ 125 $ 125 Note Payable - SF 60 60 Note Payable - SD 15,000 15,000 Note Payable - NW 715 715 Note Payable - MC #2 890 890 Convertible Note Payable - JR (5%) 42,200 (40,873 ) 1,327 69,078 Convertible Note Payable - HG (10%) 16,650 16,650 Convertible Note Payable - LGC (8%) 1 11,535 11,535 12,784 Convertible Note Payable - LGC (8%) 2 125,000 - 125,000 59,043 Convertible Note Payable - LGC (8%) 3 125,000 - - 125,000 59,194 Convertible Note Payable - LGC (8%) 4 125,000 - - 125,000 59,122 Convertible Note Payable - MLM (10%) (Related party) 41,505 - 41,505 72,071 Convertible Note Payable - LGC (8%) 5 78,750 - 78,750 54,656 Convertible Note Payable - LGC (8%) 6 52,500 (13,563 ) (185 ) 38,752 29,732 Convertible Notes Payable- PULG (8%) 1 65,000 (62,319 ) (1,907 ) 774 77,298 Convertible Notes Payable- PULG (8%) 2 58,000 (43,738 ) (1,496 ) 12,766 69,662 Convertible Notes Payable- PULG (8%) 3 43,000 (42,606 ) (2,593 ) (2,199 ) 50,143 Convertible Notes Payable- PULG (8%) 4 38,000 (30,457 ) (2,448 ) 5,095 43,308 Convertible Notes Payable- PULG (8%) 5 43,000 (25,225 ) (2,972 ) 14,803 57,866 Convertible Notes Payable- BR (12%) 1 65,000 (34,103 ) (4,534 ) 26,363 70,346 Convertible Notes Payable- CB (8%) 1 51,500 (4,708 ) (51,396 ) (1,412 ) (6,016 ) 78,975 Convertible Notes Payable- GS (8%) 1 54,000 (392 ) (53,156 ) (2,750 ) (2,298 ) 83,425 $ 1,052,430 $ (5,100 ) $ (397,436 ) $ (20,297 ) $ 629,597 $ 946,703 As of March 31, 2019, the convertible notes payable can be converted into approximately 49,753,279 shares of common stock.

Derivatives and Fair Value Inst

Derivatives and Fair Value Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
DERIVATIVES AND FAIR VALUE INSTRUMENTS	Note 6. DERIVATIVES AND FAIR VALUE INSTRUMENTS The Company applied paragraph 815-10-05-4 of the FASB Accounting Standards Codification to the 5% Convertible Notes Payable issued June 12th 2015 and the 8% Convertible Note payable issued June 25th 2015 and for the 8% Convertible Notes Payable issued January 7, 2016 and March 7, 2016, the 9% Convertible Note payable issued October 1, 2016 the 8% Convertible Notes Payable issued January 25, 2018 and June 4, 2018, the 8% convertible notes payable issued October 1, 2018 and November 19, 2018, the 8% convertible notes payable issued February 20, 2019 and February 27, 2019 and March 26, 2019 and to the 12% convertible notes payable issued January 28, 2019 and February 6, 2019 and February 25, 2019. Based on the guidance in paragraph 815-10-05-4 of the FASB Accounting Standards Codification the Company concluded these instruments were required to be accounted for as derivatives on issuance date. The Company records the fair value of the Convertible Notes Payable and certain warrants that are classified as derivatives on issuance date and the fair value changes on each reporting date reflected in the consolidated statements of operations as “Change in Fair Value - derivatives.” These derivative instruments are not designated as hedging instruments under paragraph 815-10-05-4 of the FASB Accounting Standards Codification and are disclosed on the balance sheet under Derivative Liabilities. The Company follows paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments and paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP), and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below: Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepayments and other current assets, accounts payable, and accrued expenses, approximate their fair values because of the short maturity of these instruments. The Company’s Level 3 financial liabilities consist of the 5% Convertible Notes Payable issued June 12th 2015 and the 8% Convertible Note payable issued June 25th 2015 and for the 8% Convertible Notes Payable issued January 7, 2016 and March 7, 2016 and May 1, 2017 and June 2, 2017 and July 10, 2017 and August 15, 2017, the 9% Convertible Note payable issued October 1, 2016, The 8% Convertible note payable issued January 25, 2018, the 8% Convertible note payable issued June 4, 2018 and the 8% convertible notes payable issued October 1, 2018 and November 19, 2018, the 8% convertible notes payable issued February 20, 2019 and February 27, 2019 and March 26, 2019 and to the 12% convertible notes payable issued January 28, 2019 and February 6, 2019 and February 25, 2019 for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. We have valued the automatic conditional conversion, re-pricing/down-round, change of control; default and follow-on offering provisions using a lattice model, with the assistance of a valuation consultant, for which management understands the methodologies. These models incorporate transaction details such as Company stock price, contractual terms, maturity, risk free rates, as well as assumptions about future financings, volatility, and holder behavior as of issuance and March 31, 2019. The primary assumptions include: projected annual volatility of 296%-417%; the follow-on securities purchase option; the conversion feature as a percentage of Market; automatic/conditional conversions; market price trigger events. As of March 31, 2019 the Company’s derivative financial instruments included: 1) Embedded derivatives associated with certain of the Company’s unsecured convertible notes payable. The Company’s 5% convertible notes payable and 8% convertible notes payable and 9% convertible note payable issued to unrelated investors is a hybrid instrument, which warrants separate accounting as a derivative instrument. The embedded derivative feature has been bifurcated from the debt host contract, referred to as the Derivative Liability, which resulted in a reduction of the initial carrying amount (as unamortized discount) of the Convertible Notes Payable. The unamortized discount is amortized to interest expense using the effective interest method over the life of the Notes. The embedded derivative feature includes the conversion feature within the notes and an early redemption option. The compound embedded derivatives within the convertible notes have been recorded at fair value at the date of issuance; and are marked-to-market each reporting period with changes in fair value recorded to the Company’s statement of operations as Change in fair value of derivative liabilities. The 5% Convertible Note Payable and the 8% Convertible Notes Payable, the 9% convertible note payable and the 12% convertible notes payable are valued at March 31,2019. The following assumptions were used for the valuation of the embedded derivative: - The stock price (prior period reverse split 1,000:1) of $0.0438 increased to $0.1400 then decreased to $0.0622 in this period (basis for the variable conversion prices) would fluctuate with the Company projected volatility - An event of default for the Convertible Note would occur 0% of the time, increasing 1.00% per month to a maximum of 5.0%; - Alternative financing for the Convertible Note would be initially available to redeem the note 0% of the time and increase monthly by 1% to a maximum of 10%; - Capital raising events (a single financing at 1 month from the valuation date) was previously a factor for the VV Note but are no longer projected. The full reset events projected to occur based on future stock issuance (single event) result in a reset exercise price. - The monthly trading volume would average $371,000 (rounded) as of 3/31/19 and would increase at 5% per month; ownership limits conversion across LG’s notes based on 4.99% with shares outstanding increasing monthly by 1%. - The variable conversion price of 45% to 65% over 3 to 20 trading days would have effective rates of 35.75% to 52.79%; - The Note Holders would automatically convert the notes early (and not hold to maturity) with variable conversion prices and full ratchet resets if the registration was effective and not in default; - The projected annual volatility for each valuation period was based on the historical volatility of the Company in the range 417% to 296%. The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuation. The Company’s derivative liabilities on convertible notes payable are presented at market value in the financial statements at March 31, 2019 as follows: 3/31/2019 Derivative Maturity Original Original Derivative Valuation Derivative Valuation December 31, Quarter Ended March 31, Quarter Ended March 31, Ended March 31, Derivative Valuation March 31, 5 % Convertible Note- Payable - issued 6/12/2015 4/12/2016 1/7/2017 35,863 37,827 $ 1,431 $ - (1,431 ) $ - 8% Convertible Notes Payable- issued May 1, 2016 10/28/2017 5/1/2018 131,250 103,294 $ 15,356 $ (21,462 ) 18,890 $ 12,784 8% Convertible Notes Payable- issued June 7, 2016 12/4/2017 6/7/2018 125,000 90,596 $ 22,808 36,386 $ 59,194 10% Convertible Notes Payable- issued March 8, 2016 9/15/2017 9/8/2018 150,000 167,164 $ 28,741 $ (17,244 ) 60,574 $ 72,071 8% Convertible Notes Payable- issued August 15, 2017 4/1/2018 8/15/2018 125,000 108,878 $ 22,673 $ 36,370 $ 59,043 8% Convertible Notes Payable- issued July 10, 2017 4/1/2018 7/10/2018 125,000 108,061 $ 22,743 $ 36,379 $ 59,122 8% Convertible Notes Payable- issued January 25, 2018 4/1/2018 1/25/2019 78,750 65,896 $ 8,354 $ 46,302 $ 54,656 8% Convertible Notes Payable- issued June 4, 2017 6/4/2018 6/4/2018 52,500 42,755 $ 16,972 $ 12,760 $ 29,732 8% Convertible Notes Payable- issued August 2, 2017 10/1/2018 8/2/2020 50,000 99,234 $ 51,639 $ (4,990 ) $ 22,429 $ 69,078 8% Convertible Notes Payable- issued October 1, 2018 10/1/2018 4/1/2020 58,000 49,952 $ 36,818 $ 32,844 $ 69,662 8% Convertible Notes Payable- issued November 19, 2018 11/19/2018 5/19/2020 65,000 66,134 $ 35,933 $ 41,365 $ 77,298 12% Convertible Notes Payable- issued January 28, 2019 1/28/2019 5/24/2020 43,000 $ - 26,634 $ 31,232 $ 57,866 12% Convertible Notes Payable- issued February 6, 2019 2/6/2019 11/30/2019 38,000 $ - 31,746 $ 11,562 $ 43,308 8% Convertible Notes Payable- issued February 25, 2019 2/20/2019 8/20/2020 54,000 $ - 74,826 $ 8,599 $ 83,425 12% Convertible Notes Payable- issued February 25, 2019 2/25/2019 2/25/2020 65,000 $ - 34,811 $ 35,535 $ 70,346 8% Convertible Notes Payable- issued February 27, 2019 2/27/2019 8/27/2020 51,500 $ - 75,013 $ 3,962 $ 78,975 8% Convertible Notes Payable- issued March 26, 2019 3/26/2019 9/21/2020 43,000 $ - 46,775 3,368 $ 50,143 $ 1,290,863 $ 939,791 $ 263,468 $ 289,805 $ (43,696 ) $ 437,126 $ 946,703 The Company’s mark-to-market fair value adjustment ((income)/expense) for the quarter ended March 31, 2019 totaled $437,126.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	Note 7. STOCKHOLDERS’ EQUITY Effective July 23, 2018, the Company effected a 1-for-1,000 reverse stock split of its issued and outstanding common stock. The number of shares of common stock issued and outstanding post- reverse stock split is 1,404,073. All fractional shares have been rounded up to the next whole share. There is no reduction in the number of the Company’s shareholders of record. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse stock split as if such reverse stock split occurred on the first day of the first period presented. As a result of the aforementioned reverse stock split, additional paid-in-capital was increased by $140,169 as of December 31, 2018 on the balance sheet with a corresponding decrease in the par value of common stock issued as of the same dates. The Company has authorized 4,000,000,000 shares of common stock with a par value of $0.0001 per share. Effective September 19, 2017, the Company amended its Articles of Incorporation to increase its authorized Common Stock to 4,000,000,000 shares. There were 5,808,883 and 3,482,840 shares of common stock issued and outstanding at March 31, 2019 and December 31, 2018, respectively. The Company has authorized 1,000,000 shares of Series A preferred stock with a par value of $0.0001 per share. At March 31, 2018 and December 31, 2018, there were 500,000 shares of Series A preferred stock issued and outstanding respectively. The preferred stock has preferential voting rights of 2,000 votes per outstanding share. The Company has authorized 50,000 shares of Series B convertible preferred stock with a par value of $0.0001 per share. At December 31, 2016 there were 39,000 shares issued of which 12,900 shares of Series B preferred were converted into common stock in accordance with the terms of the Series B Preferred stock. Therefore; there were 26,100 shares outstanding at December 31, 2016. The Series B preferred stock has no voting rights. During the quarter ended March 31, 2017, 18,100 shares of Series B preferred shares were converted into common stock in accordance with the terms of the Series B preferred stock. As of result there were 8,000 shares of Series B preferred shares outstanding at December 31, 2018. The holders of the Series B convertible preferred stock have the right to convert the same into Common Stock of the Corporation at the ratio of one (1) share of Series B Convertible Preferred for five hundred (500) shares of Common Stock. On October 12, 2018, the Company filed with the State of Nevada a certificate of designation pursuant to which the Company designated a new class of preferred stock as the Company’s Series C Convertible Preferred Stock (“Series C Preferred”) having a $100.00 stated value per share (“Stated Value”) and a par value equal to $0.0001 per share. The Company designated 5,000 shares of Series C Preferred. Subject to a beneficial ownership limitation equal to 4.99%, each share of Series C Preferred is convertible into 25,000 shares of the Company’s common stock. Holders of Series C Preferred are not entitled to receive dividends. In the event of any liquidation, dissolution or winding up of the Company, holders of Series C Preferred are entitled to distributions from the assets in an amount equal to, or if less, on a prorated basis, the Stated Value per share of Series C Preferred held by such holders. Holders of Series C Preferred are entitled to vote, on an as-converted basis, together with holders of Common Stock on all actions to be taken by the shareholder of the Company. During the quarter-ended December 31, 2018 the company issued 177 shares of Series C Convertible Preferred Stock for services provided to the company by various professionals. As of December 31, 2018 there are 177 shares issued and outstanding with a stated value of $17,700 and par value of $-0-. The preferred shares issued to professionals for their services were valued, in total, at $204,212 based upon a valuation using the underlying convertible feature of the company’s common stock and a Black-Scholes calculation methodology. For quarter-ended December 31, 2018, the fair value of each issuance of Series C Preferred Stock on the date of issuance is estimated using the Black-Scholes option-pricing model reflecting the following assumptions: Expected volatility 403% to 435% Expected life 0.7 Risk free interest rate 2.75% Dividend yield 0.00% During the quarter-ended March 31, 2019 the company issued 138 shares of Series C Convertible Preferred Stock for services provided to the company by various professionals. The preferred shares issued to professionals for their services were valued, in total, at $184,506 based upon a valuation using the underlying convertible feature of the company’s common stock and a Black-Scholes calculation methodology. Expected volatility 342% to 415% Expected life 0.7 Risk free interest rate 2.4% to 2.46% Dividend yield 0.00% As of March 31, 2019 there are a total of 315 shares Series C Convertible Preferred Stock issued and outstanding with a stated value of $31,500 and par value of $-0-. During the quarter ended March 31, 2018, the Company issued an aggregate 18,000 shares of common stock at prices ranging from $0.0006 to $0.0011 per share for services provided to the Company. During the quarter ended March 31, 2018, the Company issued an aggregate 376,111 shares of common stock at prices ranging from $0.0004 to $0.0006 per share as partial conversion of notes and accrued interest. During the quarter ended June 30, 2018, the Company issued an aggregate 67,500 shares of common stock at prices ranging from $0.0004 to $0.0004 per share for services provided to the Company. During the quarter ended June 30, 2018, the Company issued an aggregate 92,015 shares of common stock at prices ranging from $0.000174 to $0.00025 per share as partial conversion of notes and accrued interest. During the quarter ended September 30, 2018, the Company issued an aggregate 634,053 shares of common stock at prices ranging from $0.0525 to $0.18 per share for services provided to the Company. During the quarter ended September 30, 2018, the Company issued an aggregate 427,755 shares of common stock at prices ranging from $0.0190 to $0.1173 per share as partial conversion of notes and accrued interest. During the quarter ended December 31, 2018, the Company issued an aggregate 1,017,959 shares of common stock at prices ranging from $0.019 to $0.025 per share as partial conversion of notes and accrued interest. During the quarter ended March 31, 2019, the Company issued an aggregate 277,000 shares of common stock at a price of $0.051 per share for services provided to the Company. During the quarter ended March 31, 2019, the Company issued an aggregate 2,049,043 shares of common stock at prices ranging from $0.015 to $0.029 per share as partial conversion of notes.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 8. COMMITMENTS AND CONTINGENCIES The Company currently has three office locations. It rents offices on a month-to-month basis from the Company’s President and stockholder for $525 per month which amounted to $1,575 for the quarter-ended March 31, 2019 and 2018 respectively. The Company also has ready-to-go office space available to be used for meetings etc. at a nominal cost of approximately $100 per month with no commitment. The cost of this space for the quarter-ended March 31, 2019 and 2018 was $300. These two aforementioned commitments meet the definition of a “short-term lease” under ASC 842.20.25.2 (generally less than 12 months in duration) and therefore, the company has elected an accounting policy to not to apply the recognition requirements under ASC 842 and instead recognizes these lease payments on a straight line basis. Total rent expense for the quarter-ended March 31, 2018 was $5,822 and was $3,188 for the quarter-ended March 31, 2019. The following are the minimum required lease payments for the remainder of the lease term for the one operating lease (see below) under ASC 840: 2019 $ 18,600 2020 24,600 2021 4,100 LEASES The Company has one operating lease for its main office location occupancy. On September 12th 2016 the Company entered into a commercial lease agreement for office premises at an original cost of $650 per month for a one-year term with the option to renew for one extended term of three years. In July 2017 the Company leased additional space at this location thereby increasing the monthly rent to $1,550. A new lease was signed in March 2018 for the same space with the rent increasing to $2,050 effective January 1, 2020 (after negotiation with the landlord). The Company has no finance leases. Effective January 1, 2019, we adopted ASU 2016-02 “Leases” (Topic 842), which requires the recognition of lease assets and liabilities for items classified as operating leases under previous guidance. The original guidance required application on a modified retrospective basis with the earliest year presented. In August 2018, the FASB issued ASU 2018-11 “Targeted Improvements to ASC 842” that included an option to not restate comparative periods in transition and elect to use the effective date of Topic 842 as the date of initial application of transition, which we elected. Adoption of the new standard resulted in the recording of additional net operating lease assets and lease liabilities of $41,382 and $43,326 respectively, as of January 1, 2019. The difference between the additional lease assets and lease liabilities was recorded as deferred rent. The standard did not materially impact our statements of operations and cash flows. The required disclosures for the quarter-ended March 31, 2019 are as follows: Lease Cost: Operating lease cost $ 5,233 Other Lease Information: Cash paid for amounts in lease liabilities $ 4,650 Operating cash flows from operating leases $ 4,650 Right-of-use assets obtained in exchange for new operating lease liabilities $ 41,382 Weighted-average remaining lease term-operating leases 1.92 years Weighted-average discount rate--operating leases 8.00 % OTHER COMMITMENTS The Company has a distribution agreement with Dr. Ronald L. Rubin where upon any sales generated by him he will receive the following commissions: ● 20% for direct sales ● 5% for any sale that he oversees that involves another sales person ● 5% for any sales related to a distribution agreement. ● He is to be issued 1 Series C Preferred share or 25,000 common shares per month The Company has a distribution agreement with Dr. Gupta Pharma LLC with the following provisions: ● The Company, via its subsidiary USA Pharma, has exclusive New Jersey distribution rights for all CBD products and non-exclusive rights to all other territories. ● The agreement is for a term of 3 years, but parties have the right to terminate. ● Upon agreement signing, 120 shares of Series C Convertible Preferred stock was issued by the Company to Dr. Gupta. ● Dr. Gupta shall have 30% of the issued and outstanding common stock of the Company during the term of this agreement. Should the percentage of ownership drop below 30% then the Company must issue additional Series C Convertible Preferred Shares which are convertible into the required additional amount of common stock minus 3,000,000 shares of common stock.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	Note 9. INCOME TAXES The Company accounts for income taxes under the asset and liability approach. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. The Company's deferred tax asset consists primarily of carryforward net operating losses (NOLs). The Company believes that, at this time, it is more likely than not that the benefit of the NOLs will not be realized. As of March 31, 2019, the Company had provided a valuation allowance to fully reserve its net operating loss carryforwards and other items giving rise to deferred tax assets, primarily as a result of anticipated net losses for income tax purposes and has therefore recorded a full valuation allowance.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	Note 10. RELATED PARTY TRANSACTIONS As more fully described in Notes 3 and 4 to the Consolidated Financial Statements, the Company owed the following amounts to related parties as of the following: March 31, December 31 2019 2018 Due to Related Party $ 8,921 $ 8,921 Due to officer/stockholder 8,955 8,955 Due to other stockholders 1,100 3,100 Total Related Party Obligations $ 18,976 $ 20,976 The company has entered into an employment agreement with its Chief Executive Officer (CEO). The agreement provides for base compensation, annual bonus, benefits, vacation and reimbursements. Under this agreement, the current base compensation of the Company’s CEO is $150,000 per annum. Prior CEO employment agreements accrued $100,000 in annual salary for the years ended December 31, 2015 and 2014. In mid-year 2016 the Company commenced payroll and is paying the CEO for current wages in this manner. As of March 31, 2019, the company owes accrued compensation to it’s CEO in the amount of $403,185. As more fully described in Note 1-Intangible Asset-Licensing Agreement, on March 8th 2016 (with an effective date of October 1, 2015) the Company entered into a Licensing Agreement with a Florida Corporation (Licensor) that is owned by a related party. The Company issued 25,000 shares of Series B Preferred stock to the Licensor as partial consideration for the Licensing agreement plus a $150,000 promissory note to the Licensor for the balance of the consideration. During the quarter-ended March 31, 2016, 3,400 shares of Series B Preferred stock were converted into 1,700 shares of common stock in accordance with the terms of the Series B Preferred stock. During the quarter ended March 31, 2017, 18,100 shares of Series B preferred stock was converted into 9,050 shares of common stock in accordance with the terms of the Series B Preferred stock. As more fully described in Note 1 and Note 5 to the financial statements, $18,986 in accrued interest on the $150,000 note was satisfied through the issuance of 17,273 shares of the Company’s common stock. On September 15, 2017 the Note was amended to include provisions to allow conversion of the Note into common stock of the Company. At such time the Note was valued with it’s embedded derivative and discount. On September 25, 2017, $16,250 in principal on this note was satisfied by the conversion into 25,000 shares of the Company’s common stock. During the quarter ended March 31, 2018, $15,000 in principal on this note was satisfied by the conversion into 60,000 shares of the Company’s common stock. During the quarter ended June 30, 2018, $7,500 in principal on this note was satisfied by the conversion into 30,000 shares of the Company’s common stock. During the quarter ended June 30, 2018 the original related-party noteholder sold $20,000 in principal on this note to an unrelated third party investor thereby leaving $80,250 in principal balance due to the related party original noteholder and $20,000 in principal due to the unrelated third-party investor. During the year ended December 31, 2018 the Company made cash paydowns to the noteholder in the total amount of $32,550. In addition, $30,195 in principal balance on the note was converted into 495,000 shares of the Company’s common stock. The ending principal balance on this note at December 31, 2018 is $51,005 to the original noteholder. During the year-ended December 31, 2018 the unrelated third-party noteholder converted $3,350 in principal balance into 120,000 shares of the Company’s common stock thereby leaving a principal balance to this unrelated noteholder in the amount of $16,650. During the quarter-ended March 31, 2019 the Company made cash paydowns to the noteholder in the total amount of $5,700. In addition, $3,800 in principal balance on the note was converted into 200,000 shares of the Company’s common stock. The remaining principal balance to the original noteholder is $41,505 as of March 31, 2019 and is $16,650 to the third-party unrelated noteholder at the same date.

Basis of Reporting - Going Conc

Basis of Reporting - Going Concern	3 Months Ended
	Mar. 31, 2019
Basis of Reporting - Going Concern [Abstract]
BASIS OF REPORTING - GOING CONCERN	Note 11. BASIS OF REPORTING - GOING CONCERN The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses from inception of approximately $5,542,067 which, among other factors, raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon management’s plans to raise additional capital from the sale of stock and to receive additional financing and to commence sales of its flagship product and create revenue. The accompanying financial statements do not include any adjustments that might be required should the Company be unable to continue as a going concern. Management believes the Company’s present cash and cash equivalents will not enable it to meet its obligations for twelve months from the date these financial statements are available to be issued unless the Company received additional funding.

Stock Compensation - Equity Inc

Stock Compensation - Equity Incentive Plan	3 Months Ended
	Mar. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK COMPENSATION - EQUITY INCENTIVE PLAN	Note 12. STOCK COMPENSATION - EQUITY INCENTIVE PLAN In July 2016, the Company adopted the Medifirst Solutions, Inc. 2016 Equity Incentive Plan (the “Plan”) pursuant to which the Company may grant stock options, restricted stock purchase offers and other equity-based awards up to an aggregate of 20,000,000 shares of common stock. The Plan is designed to retain directors, executives and selected employees and consultants and reward them for making contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereby providing Participants with a proprietary interest in the growth and performance of the Company. On December 6th, 2016 the company amended the terms of the Plan and filed an S-8 Registration Statement with the Securities and Exchange Commission (“SEC”) increasing the number of shares permitted to be issued under the Plan to 32,000. During the quarter ended March 31, 2017, the Company issued from the Plan a total of 27,100 shares of common stock to non-employees for services rendered. As of March 31, 2017 there is a balance of -0- shares available for future issuance under the Medifirst Solutions, Inc. 2016 Equity Incentive Plan. In May 2017, the Company adopted the Medifirst Solutions, Inc. 2017 Equity Incentive Plan (the “2017 Plan”) pursuant to which the Company may grant stock options, restricted stock purchase offers and other equity-based awards up to an aggregate of 125,000 shares of common stock. The Plan is designed to retain directors, executives and selected employees and consultants and reward them for making contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereby providing Participants with a proprietary interest in the growth and performance of the Company. During the year ended December 31, 2017, the Company issued from the Plan 108,000 shares to non-employees for services rendered. As of December 31, 2017 there is a balance of 17,000 shares available for future issuance under the Medifirst Solutions, Inc. 2017 Equity Incentive Plan. In January 2018, the Company adopted the Medifirst Solutions, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) pursuant to which the Company may grant stock options, restricted stock purchase offers and other equity-based awards up to an aggregate of 175,000 shares of common stock. The Plan is designed to retain directors, executives and selected employees and consultants and reward them for making contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereby providing Participants with a proprietary interest in the growth and performance of the Company. During the quarter ended March 31, 2019 the Company created the Medifirst Solutions, Inc. 2019 EQUITY Incentive Plan which is designed to retain directors, executives and selected employees and consultants and reward them for making contributions to the success of the Company. These objectives are accomplished by making long-term incentive awards under the Plan thereby providing Participants with a proprietary interest in the growth and performance of the Company. The total number of shares of Common Stock which may be purchased or granted directly by Options, Stock Awards or Restricted Stock Purchase Offers, or purchased indirectly through exercise of Options granted under the Plan shall not exceed 5,000,000 shares. During the quarter ended March 31, 2018, the Company issued from the 2018 Plan a total of 4,000 shares of common stock to non-employees for services rendered. As of March 31, 2018 there is a balance of 188,000 shares available for future issuance under the Medifirst Solutions, Inc. 2018 Equity Incentive Plan. During the quarter ended June 30, 2018, the Company issued from the 2018 Plan a total of 17,500 shares of common stock to non-employees for services rendered. As of June 30, 2018 there is a balance of 170,500 shares available for future issuance under the Medifirst Solutions, Inc. 2018 Equity Incentive Plan. During the quarter ended September 30, 2018, there were no issuances from the 2018 Plan and therefore as of September 30, 2018 there is a balance of 170,500 shares available for future issuance under the Medifirst Solutions, Inc. 2018 Equity Incentive Plan. During the quarter ended December 30, 2018, there were no issuances from the 2018 Plan and therefore as of December 31, 2018 there is a balance of 170,500 shares available for future issuance under the Medifirst Solutions, Inc. 2018 Equity Incentive Plan. During the quarter ended March 31, 2019, 277,000 shares were issued from the 2019 Plan and therefore as of March 31, 2019 there is a balance of 4,723.000 shares available for future issuance under the Medifirst Solutions, Inc. 2019 Equity Incentive Plan.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 13. SUBSEQUENT EVENTS Subsequent to the quarter ended March 31, 2019 the Company issued an aggregate 3,241,450 shares of Common Stock upon conversions of an aggregate principal amount equal to $93,415 outstanding convertible promissory notes and $8,956 in accrued interest. Subsequent to the year ended December 31, 2018 the Company issued an aggregate 1 share of Series C Convertible Preferred Stock to a consultant for services performed. This 1 share of Series C Convertible Preferred Stock are convertible into 25,000 shares of common stock of the Company. The 1 share of Series C Convertible Preferred Stock will be recorded on the Company’s books at fair value using a Black-Scholes pricing model. On April 26, 2019, the Company entered into a Securities Purchase Agreement with an investor to issue a convertible promissory note in the amount of $58,000. The note pays 8% interest per annum and matures on October 20, 2020. After six months from the date of the note, the investor may convert the principal balance into common stock of the Company. On April 26, 2019 the cash funding was received by the Company and the convertible note was issued. Subsequent to the quarter ended March 31, 2019 a Series C Convertible Preferred shareholder converted 6 shares of Series C Convertible Preferred stock into 150,000 shares of common stock.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim consolidated financial statements include the accounts of Medifirst Solutions Inc. and its wholly owned subsidiary (Medical Laser Manufactures, Inc., and Concierge Concepts Rx (CCRx) (collectively referred to as the "Company"). All material intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the consolidated financial position of the Company as of March 31, 2019, the consolidated results of its operations for the three-month periods ended March 31, 2019 and 2018, the consolidated change in stockholders' equity for the three-month period ended March 31, 2019 and 2018 and the consolidated cash flows for the three-month periods ended March 31, 2017 and 2018. The results of operations for the three-month period ended March 31, 2019 are not necessarily indicative of the operating results for the full year. These financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures for the year ended December 31, 2018 included in the Company's Annual Report on Form 10-K for the year then ended. Some items in the prior year financial statements were reclassified to conform to the current presentation. Reclassifications had no effect on prior year net income or shareholders' equity. Effective July 23, 2018, the Company effected a 1-for-1,000 reverse stock split of its issued and outstanding common stock. The number of shares of common stock issued and outstanding post- reverse stock split is 1,404,073. All fractional shares have been rounded up to the next whole share. There is no reduction in the number of the Company's shareholders of record. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto have been retroactively adjusted for the reverse stock split as if such reverse stock split occurred on the first day of the first period presented.
Revenue Recognition	Revenue Recognition The Company also derives consulting revenue from it’s CCRx division. Such revenue is recognized at the time services are performed. The Company adopted the new accounting standard on revenue recognition, ASU No. 2014-09 (Topic 606) “Revenue from Contracts with Customers”, which became effective on January 1, 2018. Since the Company was classified as an Emerging Growth Company under SEC rules, ASC 606 was not adopted until January 1, 2019. Revenue is recognized at the time the product is delivered or services are performed. Provision for sales returns are estimated based on the Company’s historical return experience. Revenue is presented net of returns. The Company’s revenue recognition policy standards include the following elements under ASU No. 2014-09 (Topic 606): i. Identify the contract with a customer. In general, the contract with the customer is usually a purchase order for the sales of laser devices. For consulting work, there is a written contract with the customer and a statement of work. ii. Identify the performance obligations in the contract. The performance obligation under the laser sales contract is the shipment and delivery of the product to the customer. The performance obligations under consulting contracts is the successful performance of the consulting work detailed in the statement of work iii. Determine the transaction price. The transaction price is negotiated by the customer and the Company’s sales team and/or CEO for laser sales. For consulting work, the price is determined based upon hours and commitment of time devoted by the consultants. iv. Allocate the transaction price to the performance obligations in the contract. The transaction price is allocated to the performance obligation of the delivery of the laser product. The transaction price is allocated to the amounts contracted in the consulting agreements for consulting revenue. v. Recognize revenue when (or as) the entity satisfies a performance obligation. Upon shipment (FOB) and delivery (FOB destination) of laser products, revenue is recognized. Upon completion of statement of work in the consulting contracts revenue is recognized.
Accounts Receivable	Accounts Receivable The Company extends credit to its customers in the normal course of business and performs ongoing credit evaluations of its customers, maintaining an allowance for potential credit losses. Accounts receivable is reported net of the allowance for doubtful accounts. The allowance is based on management's estimate of the amount of receivables that will actually be collected. The Company has not recorded an allowance for doubtful accounts as of March 31, 2019 or December 31, 2018.
Inventory	Inventory Inventory consists of finished goods and is stated at the lower of cost (first-in, first-out) or market value. Finished goods inventory includes hand held laser devices, their carrying cases and goggles.
Equipment	Equipment Equipment, consisting of computer equipment, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, of five years.
Long-Lived Assets	Long-Lived Assets The Company reviews long-lived assets, such as equipment, for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds the estimated future cash flows, an impairment loss will be recorded by the amount the carrying value exceeds the fair value of the asset.
Intangible Asset- Licensing Agreement	Intangible Asset- Licensing Agreement On March 8th 2016 (with an effective date of October 1, 2015), the company, through it’s sole wholly-owned subsidiary (“Licensee”), entered into a Product and Know-How License Agreement (“Agreement”) with a Florida Corporation (“Licensor”) which is owned by a related party - the son of the Company’s CEO. The license provides with respect to the Technology, Licensor hereby grants to Licensee an irrevocable, nontransferable, royalty-bearing license, with a right of sublicense (the “License”), throughout the Territory in the Field of Use, whether or not under the Licensed Patent, to: - use or submit or deliver the Technology and/or any Product to any regulatory body throughout the Territory for purposes of obtaining approval to make, Sell, offer for Sale, import, export and distribute the Technology or Products; and - use or copy the Technology and/or any Product; and - market, make, have made, Sell, offer for Sale, import and distribute Products; and - sublicense the Technology; and - prepare, or have prepared on its behalf, modifications, enhancements and/or derivative works of the Technology. In connection with the license granted, Licensor hereby grants to Licensee a license to the Licensed Patents, whether now existing or hereafter acquired. The consideration for the licensing agreement consisted of the issuance of 25,000 Series B Preferred stock shares to the Licensor (at par) plus a $150,000 promissory note issued by the Company to the licensor. On September 15, 2017 the Note was amended to include provisions to allow conversion of the Note into common stock of the Company. On September 25, 2017, $16,250 in principal on this note was satisfied by the conversion into 25,000,000 shares of the Company’s common stock. During the quarter ended June 30, 2018, the original noteholder assigned $20,000 in principal to an unrelated third-party. There were $32,550 in cash principal paydowns to the original noteholder during the year ended December 31, 2018. There were an additional $33,345 in conversions to common stock that took place on these two notes during the year ended December 31, 2018. During the quarter-ended March 31, 2019 there were $5,700 in principal paydowns to the original noteholder and $3,800 in conversions to common stock. The principal balance on this note as of March 31, 2019 is $41,505 to the original noteholder and $16,650 in principal balance to the new unrelated third-party noteholder. The last part of the consideration in this license agreement is the royalty payments which have not taken effect yet since they are based on sales for which the company has had only minimum thus far. The licensing agreement is for a ten-year period effective from October 1, 2015. The cost of the licensing agreement is being amortized over its ten-year period and charged to income on a straight-line basis.
Product Warranty	Product Warranty We generally provide a one-year warranty on our products. Currently no material evaluations or studies have been performed to obtain warranty data since there are so few sold products outstanding. As sales increase, the Company will estimate future warranty costs from historical data and trends of product reliability and costs of repairing and replacing defective products.
Debt Issue Costs and Debt Discount	Debt Issue Costs and Debt Discount The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of convertible debt. These costs are amortized over the life of the debt to interest expense. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts are immediately expensed. Beginning in 2015, the Company adopted ASU 2015-03: Simplifying the Presentation of Debt Issuance Costs and has reflected the deferred financing costs as a direct reduction of the related debt (See table included in Note 5 to Consolidated Financial Statements).
Original Issue Discount	Original Issue Discount For certain convertible debt issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded to debt discount, reducing the face amount of the note and is amortized to interest expense over the life of the debt.
Derivative Liabilities	Derivative Liabilities Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. The Company assessed its securities for purposes of determining the proper accounting treatment and valuation as set forth in the Statement of Financial Accounting Standard ASC 820–10–35–37 Fair Value in Financial Instruments Accounting for Derivative Instruments and Hedging Activities In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments. Once the derivative liabilities are determined, they are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the condensed consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Financial Instruments	Financial Instruments The carrying amounts reported in the balance sheets for cash, accounts receivable, accounts payable, and other accrued liabilities approximate their fair values.
Segment Information	Segment Information The Company follows Accounting Standards Codification ("ASC") 280, "Segment Reporting". The Company currently operates in a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share The Company calculates net income (loss) per share based on the authoritative guidance. Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which the Company incurs losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive. As described in Note 5 to the financial statements, as of March 31, 2019, convertible debt can be converted into approximately 49,753,279 shares of common stock.
Income Taxes	Income Taxes The Company utilizes the accrual method of accounting for income taxes. Under the accrual method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and the tax basis of the assets and liabilities, and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. An allowance against deferred tax assets is recognized, when it is more likely than not, that such tax benefits will not be realized. The Company recognizes the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount recognized in the financial statements is the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax expense. The Company did not have any unrecognized tax benefits as of March 31, 2019, and does not expect this to change significantly over the next 12 months.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with ASC 718, Compensation - Stock Compensation. ASC 718 requires all share-based compensation payments to be recognized in the financial statements based on the fair value on the issuance date. The Company adopted the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 did not have any impact on the Company's financial statement presentation or disclosures. The Company did not have any equity instruments that required revaluation under this new standard.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At December 31, 2018 and March 31, 2019, the Company had $83,382 and $275,705 in cash equivalents respectively.
Recent Pronouncements	Recent Pronouncements The Company is no longer an “emerging growth company” as defined in Section 2(a)(19) of the Securities Act. In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract”, which align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal use software license). ASU 2018-15 is effective for the Company beginning in the first fiscal quarter of 2022, with early adoption permitted. The Company is currently evaluating the impact of this ASU on the consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments,” which amends the guidance on measuring credit losses on financial assets held at amortized cost. The amendment is intended to address the issue that the previous “incurred loss” methodology was restrictive for an entity’s ability to record credit losses based on not yet meeting the “probable” threshold. The new language will require these assets to be valued at amortized cost presented at the net amount expected to be collected with a valuation provision. This update standard is effective for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this ASU on the consolidated financial statements. In August 2018, the Securities and Exchange Commission (the “SEC”) issued a final rule that amends certain of the SEC’s disclosure requirements, including requirements relating to disclosures about changes in stockholders’ equity. For Quarterly Reports on Form 10-Q, the final rule extends to interim periods the annual requirement in Rule 3-04 of Regulation S-X, to disclose (1) changes in stockholders’ equity and (2) the amount of dividends per share for each class of shares (as opposed to common stock only, as previously required). Pursuant to the final rule, registrants must now analyze changes in stockholders’ equity, in the form of a reconciliation, for “the current and comparative year-to-date [interim] periods, with subtotals for each interim period,” i.e., a reconciliation covering each period for which an income statement is presented. Rule 3-04 of Regulation S-X permits the disclosure of changes in stockholders’ equity (including dividend-per-share amounts) to be made either in a separate financial statement or in the notes to the financial statements. The final rule is effective for all filings made on or after November 5, 2018. SEC staff has indicated it would not object if a registrant’s first presentation of the changes in shareholders’ equity is included in its Form 10-Q for the quarter that begins after the effective date of the amendments. Therefore, the Company conformed to this rule in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.

Property, Plant and Equipment_2

Property, Plant and Equipment (Net) (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Summary of equipment recorded at cost	March 31, December 31, Computer equipment $ 8,956 $ 8,956 Less: accumulated depreciation (8,525 ) (8,365 ) $ 432 $ 592

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Short-term Debt [Line Items]
Schedule of derivative liabilities	3/31/2019 Remaining Original Deferred Total Principal Issue Derivative Financing Convertible Derivative Debt Amount Discount Discount Costs Notes Payable Liability Note Payable - BS $ 125 $ 125 Note Payable - SF 60 60 Note Payable - SD 15,000 15,000 Note Payable - NW 715 715 Note Payable - MC #2 890 890 Convertible Note Payable - JR (5%) 42,200 (40,873 ) 1,327 69,078 Convertible Note Payable - HG (10%) 16,650 16,650 Convertible Note Payable - LGC (8%) 1 11,535 11,535 12,784 Convertible Note Payable - LGC (8%) 2 125,000 - 125,000 59,043 Convertible Note Payable - LGC (8%) 3 125,000 - - 125,000 59,194 Convertible Note Payable - LGC (8%) 4 125,000 - - 125,000 59,122 Convertible Note Payable - MLM (10%) (Related party) 41,505 - 41,505 72,071 Convertible Note Payable - LGC (8%) 5 78,750 - 78,750 54,656 Convertible Note Payable - LGC (8%) 6 52,500 (13,563 ) (185 ) 38,752 29,732 Convertible Notes Payable- PULG (8%) 1 65,000 (62,319 ) (1,907 ) 774 77,298 Convertible Notes Payable- PULG (8%) 2 58,000 (43,738 ) (1,496 ) 12,766 69,662 Convertible Notes Payable- PULG (8%) 3 43,000 (42,606 ) (2,593 ) (2,199 ) 50,143 Convertible Notes Payable- PULG (8%) 4 38,000 (30,457 ) (2,448 ) 5,095 43,308 Convertible Notes Payable- PULG (8%) 5 43,000 (25,225 ) (2,972 ) 14,803 57,866 Convertible Notes Payable- BR (12%) 1 65,000 (34,103 ) (4,534 ) 26,363 70,346 Convertible Notes Payable- CB (8%) 1 51,500 (4,708 ) (51,396 ) (1,412 ) (6,016 ) 78,975 Convertible Notes Payable- GS (8%) 1 54,000 (392 ) (53,156 ) (2,750 ) (2,298 ) 83,425 $ 1,052,430 $ (5,100 ) $ (397,436 ) $ (20,297 ) $ 629,597 $ 946,703
Notes converted $110 [Member]
Short-term Debt [Line Items]
Schedule of convertible note conversion	Date of Conversion Principal Conversion Shares June 2013 $ 70 $ 0.0001 700 August 2013 $ 40 $ 0.0001 400
New note holder converted an additional $90 [Member]
Short-term Debt [Line Items]
Schedule of convertible note conversion	Date of Conversion Principal Conversion Shares November 2013 $ 40 $ 0.0001 400 December 2013 $ 50 $ 0.0001 500
New note holder converted an additional $90 one [Member]
Short-term Debt [Line Items]
Schedule of convertible note conversion	Date of Conversion Principal Conversion Shares March 2014 $ 50 $ 0.0001 500 April 2014 $ 40 $ 0.0001 400
Note converted $1,010 [Member]
Short-term Debt [Line Items]
Schedule of convertible note conversion	Date of Conversion Principal Conversion Shares December 2012 $ 150 $ 0.001 150 January 2013 $ 660 $ 0.001 660 March 2013 $ 200 $ 0.001 200

Derivatives and Fair Value In_2

Derivatives and Fair Value Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of derivative liabilities on convertible notes payable	3/31/2019 Derivative Maturity Original Original Derivative Valuation Derivative Valuation December 31, Quarter Ended March 31, Quarter Ended March 31, Ended March 31, Derivative Valuation March 31, 5 % Convertible Note- Payable - issued 6/12/2015 4/12/2016 1/7/2017 35,863 37,827 $ 1,431 $ - (1,431 ) $ - 8% Convertible Notes Payable- issued May 1, 2016 10/28/2017 5/1/2018 131,250 103,294 $ 15,356 $ (21,462 ) 18,890 $ 12,784 8% Convertible Notes Payable- issued June 7, 2016 12/4/2017 6/7/2018 125,000 90,596 $ 22,808 36,386 $ 59,194 10% Convertible Notes Payable- issued March 8, 2016 9/15/2017 9/8/2018 150,000 167,164 $ 28,741 $ (17,244 ) 60,574 $ 72,071 8% Convertible Notes Payable- issued August 15, 2017 4/1/2018 8/15/2018 125,000 108,878 $ 22,673 $ 36,370 $ 59,043 8% Convertible Notes Payable- issued July 10, 2017 4/1/2018 7/10/2018 125,000 108,061 $ 22,743 $ 36,379 $ 59,122 8% Convertible Notes Payable- issued January 25, 2018 4/1/2018 1/25/2019 78,750 65,896 $ 8,354 $ 46,302 $ 54,656 8% Convertible Notes Payable- issued June 4, 2017 6/4/2018 6/4/2018 52,500 42,755 $ 16,972 $ 12,760 $ 29,732 8% Convertible Notes Payable- issued August 2, 2017 10/1/2018 8/2/2020 50,000 99,234 $ 51,639 $ (4,990 ) $ 22,429 $ 69,078 8% Convertible Notes Payable- issued October 1, 2018 10/1/2018 4/1/2020 58,000 49,952 $ 36,818 $ 32,844 $ 69,662 8% Convertible Notes Payable- issued November 19, 2018 11/19/2018 5/19/2020 65,000 66,134 $ 35,933 $ 41,365 $ 77,298 12% Convertible Notes Payable- issued January 28, 2019 1/28/2019 5/24/2020 43,000 $ - 26,634 $ 31,232 $ 57,866 12% Convertible Notes Payable- issued February 6, 2019 2/6/2019 11/30/2019 38,000 $ - 31,746 $ 11,562 $ 43,308 8% Convertible Notes Payable- issued February 25, 2019 2/20/2019 8/20/2020 54,000 $ - 74,826 $ 8,599 $ 83,425 12% Convertible Notes Payable- issued February 25, 2019 2/25/2019 2/25/2020 65,000 $ - 34,811 $ 35,535 $ 70,346 8% Convertible Notes Payable- issued February 27, 2019 2/27/2019 8/27/2020 51,500 $ - 75,013 $ 3,962 $ 78,975 8% Convertible Notes Payable- issued March 26, 2019 3/26/2019 9/21/2020 43,000 $ - 46,775 3,368 $ 50,143 $ 1,290,863 $ 939,791 $ 263,468 $ 289,805 $ (43,696 ) $ 437,126 $ 946,703

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of fair value issuance is estimated using Black-Scholes option-pricing model assumptions	Expected volatility 403% to 435% Expected life 0.7 Risk free interest rate 2.75% Dividend yield 0.00% Expected volatility 342% to 415% Expected life 0.7 Risk free interest rate 2.4% to 2.46% Dividend yield 0.00%

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of minimum required lease payments	2019 $ 18,600 2020 24,600 2021 4,100
Schedule of agreements with consultants for ongoing services for commitments	Lease Cost: Operating lease cost $ 5,233 Other Lease Information: Cash paid for amounts in lease liabilities $ 4,650 Operating cash flows from operating leases $ 4,650 Right-of-use assets obtained in exchange for new operating lease liabilities $ 41,382 Weighted-average remaining lease term-operating leases 1.92 years Weighted-average discount rate--operating leases 8.00 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Schedule of owed amounts to related parties	March 31, December 31 2019 2018 Due to Related Party $ 8,921 $ 8,921 Due to officer/stockholder 8,955 8,955 Due to other stockholders 1,100 3,100 Total Related Party Obligations $ 18,976 $ 20,976

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended					2 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Jul. 23, 2018	Apr. 18, 2018	Sep. 25, 2017	Aug. 19, 2015	Jul. 31, 2018	Mar. 31, 2019	Dec. 31, 2018
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Reverse stock split, description		The Company effected a 1-for-1,000 reverse stock split of its issued and outstanding common stock. The number of shares of common stock issued and outstanding post- reverse stock split is 1,404,073.
Shares conversions of common stock							49,753,279
Cash equivalents	$ 275,705						$ 275,705	$ 83,382
Ownership percentage, Description			The Company incorporated Concierge Concepts Rx (CCRx), in the State of New Jersey, to be an 80% majority-owned subsidiary. In consideration for his contribution of know-how, CCRx's co-founder, Walter Molokie, CCRx has agreed to issue a 20% minority interest in CCRx to Mr. Molokie and/or his designees.
Series B Preferred stock [Member]
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Issuance of shares	25,000			25,000,000
Promissory note issued	$ 150,000
Principal note amount				$ 16,250
Two Notes [Member]
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Conversions to common stock								33,345
Medical Lasers Manufacturer, Inc [Member]
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Equity interest, percentage					100.00%
Total purchase shares price					20,000
Common stock per share					$ 0.001
Common stock value					$ 20
Fair value of acquired entity					$ 20
Concierge Concepts Rx [Member]
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Equity interest, percentage						100.00%
Total purchase shares price						20
Total purchase price						$ 20
Payments of cash						$ 20
Unrelated Third-Party [Member]
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Principal balance	16,650						16,650
Cash principal paydowns								$ 32,550
Original Noteholder [Member]
Nature of Operations and Summary of Significant Accounting Policies (Textual)
Principal balance	41,505						41,505
Conversions to common stock							3,800
Principal note amount	$ 5,700						$ 5,700

Property, Plant and Equipment_3

Property, Plant and Equipment (Net) (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Computer equipment	$ 8,956	$ 8,956
Less: accumulated depreciation	(8,525)	(8,365)
Total	$ 432	$ 592

Property, Plant and Equipment_4

Property, Plant and Equipment (Net) (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property, Plant and Equipment (Net) (Textual)
Depreciation expense	$ 159	$ 159

Due to Related Party (Details)

Due to Related Party (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Due to Related Party (Textual)
Due to related party	$ 8,921	$ 8,921

Loans Payable - Stockholders (D

Loans Payable - Stockholders (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Apr. 30, 2014	Dec. 31, 2012
Loans Payable - Stockholders (Textual)
Stockholder of company advance	$ 0	$ 0
Loan	$ 6,375	8,375
Subsequent event, Description	The note holder transferred $2,500 of note principal to third parties and the new holders converted their holdings into 2,500 shares of the Company's common stock. During 2015, the original note holder transferred an additional $2,400 of note principal to third parties who converted their holdings into 2,400 shares of the Company's common stock.
Promissory Note [Member]
Loans Payable - Stockholders (Textual)
Shareholder indebted amount				$ 5,000
Conversion price per share			$ 0.0001
Loan balance	$ 100	100
Promissory Note [Member] | Stockholder [Member]
Loans Payable - Stockholders (Textual)
Shareholder indebted amount	$ 1,000	$ 1,000
Interest rate	26.70%
Promissory note due date	Jan. 1, 2014

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - Notes converted $110 [Member]	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
June 2013 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 70
Conversion Rate | $ / shares	$ 0.0001
Shares Received | shares	700
August 2013 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 40
Conversion Rate | $ / shares	$ 0.0001
Shares Received | shares	400

Convertible Notes Payable (De_2

Convertible Notes Payable (Details 1) - New note holder converted an additional $90 [Member]	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
November 2013 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 40
Conversion Rate | $ / shares	$ 0.0001
Shares Received | shares	400
December 2013 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 50
Conversion Rate | $ / shares	$ 0.0001
Shares Received | shares	500

Convertible Notes Payable (De_3

Convertible Notes Payable (Details 2) - New note holder converted an additional $90 one [Member]	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
March 2014 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 50
Conversion Rate | $ / shares	$ 0.0001
Shares Received | shares	500
April 2014 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 40
Conversion Rate | $ / shares	$ 0.0001
Shares Received | shares	400

Convertible Notes Payable (De_4

Convertible Notes Payable (Details 3) - Note converted $1,010 [Member]	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
December 2012 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 150
Conversion Rate | $ / shares	$ 0.001
Shares Received | shares	150
January 2013 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 660
Conversion Rate | $ / shares	$ 0.001
Shares Received | shares	660
March 2013 [Member]
Debt Conversion [Line Items]
Principal Amount Converted | $	$ 200
Conversion Rate | $ / shares	$ 0.001
Shares Received | shares	200

Convertible Notes Payable (De_5

Convertible Notes Payable (Details 4) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Short-term Debt [Line Items]
Remaining Principal Amount	$ 1,052,430
Original Issue Discount	(5,100)
Derivative Discount	(397,436)
Deferred Financing Costs	(20,297)
Total Convertible Notes Payable	588,092	$ 522,446
Derivative Liability	946,703	$ 263,468
Note Payable - BS [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	125
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	125
Derivative Liability
Note Payable - SF [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	60
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	60
Derivative Liability
Note Payable - SD [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	15,000
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	15,000
Derivative Liability
Note Payable - NW [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	715
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	715
Derivative Liability
Note Payable - MC #2 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	890
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	890
Derivative Liability
Convertible Note Payable - JR (5%) [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	42,200
Original Issue Discount
Derivative Discount	(40,873)
Deferred Financing Costs
Total Convertible Notes Payable	1,327
Derivative Liability	69,078
Convertible Note Payable - HG (10%) [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	16,650
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	16,650
Derivative Liability
Convertible Note Payable - LGC (8%) 1 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	11,535
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	11,535
Derivative Liability	12,784
Convertible Note Payable - LGC (8%) 2 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	125,000
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	125,000
Derivative Liability	59,043
Convertible Note Payable - LGC (8%) 3 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	125,000
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	125,000
Derivative Liability	59,194
Convertible Note Payable - LGC (8%) 4 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	125,000
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	125,000
Derivative Liability	59,122
Convertible Note Payable - MLM (10%) (Related party) [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	41,505
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	41,505
Derivative Liability	72,071
Convertible Note Payable - LGC (8%) 5 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	78,750
Original Issue Discount
Derivative Discount
Deferred Financing Costs
Total Convertible Notes Payable	78,750
Derivative Liability	54,656
Convertible Note Payable - LGC (8%) 6 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	52,500
Original Issue Discount
Derivative Discount	(13,563)
Deferred Financing Costs	(185)
Total Convertible Notes Payable	38,752
Derivative Liability	29,732
Convertible Notes Payable- PULG (8%) 1 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	65,000
Original Issue Discount
Derivative Discount	(62,319)
Deferred Financing Costs	(1,907)
Total Convertible Notes Payable	774
Derivative Liability	77,298
Convertible Notes Payable- PULG (8%) 2 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	58,000
Original Issue Discount
Derivative Discount	(43,738)
Deferred Financing Costs	(1,496)
Total Convertible Notes Payable	12,766
Derivative Liability	69,662
Convertible Notes Payable- PULG (8%) 3 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	43,000
Original Issue Discount
Derivative Discount	(42,606)
Deferred Financing Costs	(2,593)
Total Convertible Notes Payable	(2,199)
Derivative Liability	50,143
Convertible Notes Payable- PULG (8%) 4 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	38,000
Original Issue Discount
Derivative Discount	(30,457)
Deferred Financing Costs	(2,448)
Total Convertible Notes Payable	5,095
Derivative Liability	43,308
Convertible Notes Payable- PULG (8%) 5 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	43,000
Original Issue Discount
Derivative Discount	(25,225)
Deferred Financing Costs	(2,972)
Total Convertible Notes Payable	14,803
Derivative Liability	57,866
Convertible Notes Payable- BR (12%) 1 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	65,000
Original Issue Discount
Derivative Discount	(34,103)
Deferred Financing Costs	(4,534)
Total Convertible Notes Payable	26,363
Derivative Liability	70,346
Convertible Notes Payable- CB (8%) 1 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	51,500
Original Issue Discount	(4,708)
Derivative Discount	(51,396)
Deferred Financing Costs	(1,412)
Total Convertible Notes Payable	(6,016)
Derivative Liability	78,975
Convertible Notes Payable- GS (8%) 1 [Member]
Short-term Debt [Line Items]
Remaining Principal Amount	54,000
Original Issue Discount	(392)
Derivative Discount	(53,156)
Deferred Financing Costs	(2,750)
Total Convertible Notes Payable	(2,298)
Derivative Liability	$ 83,425

Convertible Notes Payable (De_6

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended															3 Months Ended		12 Months Ended
	Apr. 30, 2017	Jan. 31, 2017	Aug. 31, 2016	Apr. 30, 2015	Oct. 31, 2014	Apr. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Nov. 30, 2013	Oct. 31, 2013	Sep. 30, 2013	Aug. 31, 2013	Jul. 31, 2013	May 31, 2012	Mar. 31, 2011	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2012
Convertible Notes Payable (Textual)
Retired amount of notes																$ 5,700
Note Payable-BS [Member]
Convertible Notes Payable (Textual)
Maturity of convertible notes															January 2012
Amount of accrued interest transferred												$ 55
Interest rate on notes															6.00%
Converted shares of common stock											1,000
Principal amount converted											$ 100	$ 330
Issued aggregate principal amount															$ 800
Note Payable-BS [Member] | Notes converted $110 [Member]
Convertible Notes Payable (Textual)
Converted shares of common stock															1,100
Principal amount converted															$ 110
Note Payable-BS [Member] | New note holder converted an additional $90 [Member]
Convertible Notes Payable (Textual)
Converted shares of common stock						900,000	900,000	900,000	900,000
Principal amount converted						$ 90	$ 90	$ 90	$ 90
Remaining principal of note																$ 125
Note Payable-BS [Member] | Third Party [Member]
Convertible Notes Payable (Textual)
Converted shares of common stock											350	50
Principal amount converted											$ 35	$ 5
Note Payable-SF [Member]
Convertible Notes Payable (Textual)
Note conversion, maximum shares issuable in percentage of issued and outstanding common stock																9.99%		9.99%
Interest rate on notes																0.01%		0.01%
Conversion price per share													$ 0.0006
Converted shares of common stock													400			580,307		347,936
Principal amount converted													$ 240
Remaining principal of note																$ 60		$ 60
Note Payable-NW [Member]
Convertible Notes Payable (Textual)
Note conversion, maximum shares issuable in percentage of issued and outstanding common stock																9.99%		9.99%
Conversion price per share										$ 0.001						$ 0.001		$ 0.001
Converted shares of common stock			3,000,000		1,100					400
Principal amount converted			$ 3,000		$ 1,100					$ 400
Remaining principal of note																$ 715		$ 715
Description of conversion of convertible notes													In August 2013, in a private transaction, the new note holder of the aforementioned note transferred $4,475 of principal to a stockholder of the company.
Issued aggregate principal amount													$ 9,690
Issuance of common shares																49,753,279		347,936
Note Payable-RK [Member]
Convertible Notes Payable (Textual)
Maturity of convertible notes														November 2012
Note conversion, maximum shares issuable in percentage of issued and outstanding common stock														9.99%
Retired amount of notes													$ 14,000
Interest rate on notes														6.00%					6.00%
Conversion price per share														$ 0.001
Converted shares of common stock													300	1,010
Principal amount converted													$ 300	$ 1,010
Description of conversion of convertible notes														The note plus any accrued but unpaid interest were convertible at the rate of $0.001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock.
Issued aggregate principal amount														$ 25,000
Note Payable-RK [Member] | Third Party [Member]
Convertible Notes Payable (Textual)
Issued aggregate principal amount													$ 9,690
Note Payable-MC #2 [Member]
Convertible Notes Payable (Textual)
Maturity of convertible notes				October 2015
Note conversion, maximum shares issuable in percentage of issued and outstanding common stock				8.00%
Principal amount transferred to shareholders/third party		$ 600
Converted shares of common stock	6,000	11,000
Principal amount converted	$ 410	$ 1,100
Remaining principal of note																$ 890		$ 890
Description of conversion of convertible notes				The holder of the note has the right to convert the principal into shares of the Company's common stock at any time 180 days after the closing date at $0.0001 per share. Interest on the note accrues interest at 8% per annum and is payable when the note matures.
Issued aggregate principal amount				$ 3,000
Issuance of common shares		6,000

Convertible Notes Payable (De_7

Convertible Notes Payable (Details Textual 1) - USD ($)	Mar. 26, 2019	Feb. 27, 2019	Feb. 25, 2019	Feb. 20, 2019	Feb. 04, 2019	Jan. 24, 2019	Oct. 02, 2018	Jun. 04, 2018	Jan. 25, 2018	Sep. 25, 2017	Aug. 02, 2017	Jun. 02, 2017	May 01, 2017	May 02, 2016	Mar. 08, 2016	Nov. 19, 2018	Dec. 31, 2017	Sep. 25, 2017	Jun. 30, 2017	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Apr. 30, 2014
Convertible Notes Payable (Textual)
Gain on debt settlement																				$ 10,561
Original issue, discount																				(5,100)
Convertible notes payable																				$ 588,092	$ 522,446					$ 522,446
Conversion price, description																				The noteholder converted $5,813 of interest and penalty into 398,859 shares of common stock of the Company and $9,815 was paid in cash to the noteholder by the Company thereby resulting in a recognized loss on the extinguishment of the debt in the amount of $2,732.
Convertible notes payable, principal amount																				$ 1,290,863
Conversion of stock, shares																				49,753,279
Promissory Note [Member]
Convertible Notes Payable (Textual)
Conversion price per share																												$ 0.0001
Convertible notes payable, principal amount										$ 16,250								$ 16,250						$ 15,000
Accrued interest																				$ 18,986
Common stock issued on fully satisfied issuance																				17,273
Conversion of stock, shares																		25,000						60,000
Convertible Notes Payable - PULG (8%) [Member]
Convertible Notes Payable (Textual)
Interest rate on notes	8.00%				12.00%	12.00%	8.00%									8.00%
Promissory note due date	Sep. 21, 2020				Nov. 30, 2019	May 24, 2020	Apr. 1, 2020									May 19, 2020
Convertible notes payable, principal amount	$ 43,000				$ 38,000	$ 43,000	$ 58,000									$ 65,000				$ 43,000
Convertible Notes Payable-SO (8%) [Member]
Convertible Notes Payable (Textual)
Interest rate on notes														8.00%
Promissory note due date														May 2, 2017
Conversion date, description														The holder of the note is entitled, at its option beginning on the 6 month anniversary, to convert all or any of the principal face amount of the Note then outstanding into shares of the Company's common stock at the price equal to 55% of the lowest trading price for the twenty prior trading days including the date of conversion.
Debt discounted rate, percentage														10.00%
Convertible notes payable converted into common stock																								122,727	23,490
Remaining principal of note																	$ 25,452						$ 2,452				$ 25,452
Principal amount converted																								$ 23,000	$ 32,298
Convertible notes payable, principal amount														$ 57,750
Accrued interest																					12,896					$ 12,896
Conversion of stock, shares																										148,316
Convertible Notes Payable - Funding [Member]
Convertible Notes Payable (Textual)
Convertible notes payable converted into common stock																											35,058
Sale of convertible redeemable principal amount													$ 1,012,500
Total of were actually funded													$ 506,250
Debt instrument convertible redeemable description													On May 1st, 2017 and June 2, 2017, the Company and the Investor conducted the first two closings under the Purchase Agreement, pursuant to which the Company issued to the Investor (i) a convertible redeemable note in principal amount of $131,250 (the "$131K Note"); and (ii) a convertible redeemable note in principal amount of $125,000 (the "$125K Note"). On July 10, 2017 and August 7, 2017, the Company and the Investor conducted the second two closings under the Purchase Agreement, pursuant to which the Company issued to the Investor two convertible redeemable notes each in the principal amount of $125,000;
Remaining principal of note																	94,400			11,535							$ 94,400
Principal amount converted																						$ 2,200	$ 10,030	$ 38,870			21,500
Convertible notes payable, principal amount												$ 125,000	$ 131,250				131,250			21,125	10,640					$ 10,640	$ 131,250
Accrued interest																				$ 2,977	$ 1,312					1,312
Conversion of stock, shares																				1,249,684	148,545	69,439	62,015	193,384			39,714
Convertible notes issued date												Dec. 4, 2017	Oct. 28, 2017
Principal outstanding balance																											$ 15,350
Convertible Notes Payable - JR (5%) [Member]
Convertible Notes Payable (Textual)
Interest rate on notes											5.00%
Promissory note due date											Aug. 2, 2018
Conversion price per share											$ 0.003
Remaining principal of note																				$ 42,200
Principal amount converted											$ 50,000
Convertible notes payable, principal amount																				$ 3,300	$ 4,500					$ 4,500
Common stock issued on fully satisfied issuance																				200,000						150,000
Convertible Notes Payable - MLM (10%) [Member]
Convertible Notes Payable (Textual)
Convertible notes payable																				$ 41,505
Unrelated noteholder																				16,650
Convertible Notes Payable - MLM (10%) [Member] | Common Stock [Member]
Convertible Notes Payable (Textual)
Principal amount converted																										$ 3,350
Conversion of stock, shares																										120,000
Unrelated noteholder																										$ 16,650
Convertible Notes Payable - MLM (10%) [Member] | Promissory Notes [Member]
Convertible Notes Payable (Textual)
Convertible notes payable																				5,700	32,550					32,550
Convertible notes payable, principal amount										$ 16,250								$ 16,250		$ 3,800	$ 30,195					$ 30,195
Promissory note issued by company															$ 150,000
Accrued interest																			$ 18,986
Common stock issued on fully satisfied issuance										25,000									17,273							495,000
Conversion of stock, shares																				200,000
Issuance of series B preferred shares as part consideration for license agreement, shares															25,000
Leaving balance on original note																	$ 133,750
Principal outstanding balance																										$ 51,005
Convertible Notes Payable - LG (8%) [Member]
Convertible Notes Payable (Textual)
Promissory note due date									Jan. 25, 2019
Convertible notes payable, principal amount																				$ 52,500
Convertible Notes Payable - LG (8%) [Member] | Promissory Note [Member]
Convertible Notes Payable (Textual)
Interest rate on notes								8.00%	8.00%
Promissory note due date								Jun. 4, 2019
Convertible notes payable, principal amount								$ 52,500	$ 78,750											78,750
Convertible Notes Payable - PULG (8%) [Member]
Convertible Notes Payable (Textual)
Convertible notes payable, principal amount					$ 38,000
Convertible Notes Payable - PULG (8%) [Member]
Convertible Notes Payable (Textual)
Convertible notes payable, principal amount																				43,000
Convertible Notes Payable - BR (12%) [Member]
Convertible Notes Payable (Textual)
Interest rate on notes			12.00%
Promissory note due date			Feb. 25, 2020
Convertible notes payable, principal amount			$ 65,000																	65,000
Convertible Notes Payable - CB (8%) [Member]
Convertible Notes Payable (Textual)
Interest rate on notes		8.00%
Promissory note due date		Aug. 20, 2020
Convertible notes payable, principal amount		$ 51,500																		51,500
Convertible Notes Payable - GS (8%) [Member]
Convertible Notes Payable (Textual)
Interest rate on notes				8.00%
Promissory note due date				Aug. 20, 2020
Convertible notes payable, principal amount				$ 54,000																$ 54,000

Derivatives and Fair Value In_3

Derivatives and Fair Value Instruments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Derivative [Line Items]
Original Principal Note Amount	$ 1,290,863
Original Derivative Valuation	939,791
Issuances	289,805
Conversions	(43,696)
Mark-to-Market	437,126
Derivative Valuation	$ 946,703	$ 263,468
5 % Convertible Note- Payable - issued 6/12/2015 [Member]
Derivative [Line Items]
Derivative Treatment Date	Apr. 12, 2016
Maturity Date	Jan. 7, 2017
Original Principal Note Amount	$ 35,863
Original Derivative Valuation	37,827
Conversions
Mark-to-Market	(1,431)
Derivative Valuation		1,431
8% Convertible Notes Payable- issued May 1, 2016 [Member]
Derivative [Line Items]
Derivative Treatment Date	Oct. 28, 2017
Maturity Date	May 1, 2018
Original Principal Note Amount	$ 131,250
Original Derivative Valuation	103,294
Conversions	(21,462)
Mark-to-Market	18,890
Derivative Valuation	$ 12,784	15,356
8% Convertible Notes Payable- issued June 7, 2016 [Member]
Derivative [Line Items]
Derivative Treatment Date	Dec. 4, 2017
Maturity Date	Jun. 7, 2018
Original Principal Note Amount	$ 125,000
Original Derivative Valuation	90,596
Mark-to-Market	36,386
Derivative Valuation	$ 59,194	22,808
10% Convertible Notes Payable- issued March 8, 2016 [Member]
Derivative [Line Items]
Derivative Treatment Date	Sep. 15, 2017
Maturity Date	Sep. 8, 2018
Original Principal Note Amount	$ 150,000
Original Derivative Valuation	167,164
Conversions	(17,244)
Mark-to-Market	60,574
Derivative Valuation	$ 72,071	28,741
8% Convertible Notes Payable- issued August 15, 2017 [Member]
Derivative [Line Items]
Derivative Treatment Date	Apr. 1, 2018
Maturity Date	Aug. 15, 2018
Original Principal Note Amount	$ 125,000
Original Derivative Valuation	108,878
Mark-to-Market	36,370
Derivative Valuation	$ 59,043	22,673
8% Convertible Notes Payable- issued July 10, 2017 [Member]
Derivative [Line Items]
Derivative Treatment Date	Apr. 1, 2018
Maturity Date	Jul. 10, 2018
Original Principal Note Amount	$ 125,000
Original Derivative Valuation	108,061
Mark-to-Market	36,379
Derivative Valuation	$ 59,122	22,743
8% Convertible Notes Payable- issued January 25, 2018 [Member]
Derivative [Line Items]
Derivative Treatment Date	Apr. 1, 2018
Maturity Date	Jan. 25, 2019
Original Principal Note Amount	$ 78,750
Original Derivative Valuation	65,896
Mark-to-Market	46,302
Derivative Valuation	$ 54,656	8,354
8% Convertible Notes Payable- issued June 4, 2017 [Member]
Derivative [Line Items]
Derivative Treatment Date	Jun. 4, 2018
Maturity Date	Jun. 4, 2018
Original Principal Note Amount	$ 52,500
Original Derivative Valuation	42,755
Mark-to-Market	12,760
Derivative Valuation	$ 29,732	16,972
8% Convertible Notes Payable- issued August 2, 2017 [Member]
Derivative [Line Items]
Derivative Treatment Date	Oct. 1, 2018
Maturity Date	Aug. 2, 2020
Original Principal Note Amount	$ 50,000
Original Derivative Valuation	99,234
Conversions	(4,990)
Mark-to-Market	22,429
Derivative Valuation	$ 69,078	51,639
8% Convertible Notes Payable- issued October 1, 2018 [Member]
Derivative [Line Items]
Derivative Treatment Date	Oct. 1, 2018
Maturity Date	Apr. 1, 2020
Original Principal Note Amount	$ 58,000
Original Derivative Valuation	49,952
Mark-to-Market	32,844
Derivative Valuation	$ 69,662	36,818
8% Convertible Notes Payable- issued November 19, 2018 [Member]
Derivative [Line Items]
Derivative Treatment Date	Nov. 19, 2018
Maturity Date	May 19, 2020
Original Principal Note Amount	$ 65,000
Original Derivative Valuation	66,134
Mark-to-Market	41,365
Derivative Valuation	$ 77,298	35,933
12% Convertible Notes Payable- issued January 28, 2019 [Member]
Derivative [Line Items]
Derivative Treatment Date	Jan. 28, 2019
Maturity Date	May 24, 2020
Original Principal Note Amount	$ 43,000
Issuances	26,634
Mark-to-Market	31,232
Derivative Valuation	$ 57,866
12% Convertible Notes Payable- issued February 6, 2019 [Member]
Derivative [Line Items]
Derivative Treatment Date	Feb. 6, 2019
Maturity Date	Nov. 30, 2019
Original Principal Note Amount	$ 38,000
Issuances	31,746
Mark-to-Market	11,562
Derivative Valuation	$ 43,308
8% Convertible Notes Payable- issued February 25, 2019 [Member]
Derivative [Line Items]
Derivative Treatment Date	Feb. 20, 2019
Maturity Date	Aug. 20, 2020
Original Principal Note Amount	$ 54,000
Issuances	74,826
Mark-to-Market	8,599
Derivative Valuation	$ 83,425
12% Convertible Notes Payable- issued February 25, 2019 [Member]
Derivative [Line Items]
Derivative Treatment Date	Feb. 25, 2019
Maturity Date	Feb. 25, 2020
Original Principal Note Amount	$ 65,000
Issuances	34,811
Mark-to-Market	35,535
Derivative Valuation	$ 70,346
8% Convertible Notes Payable- issued February 27, 2019 [Member]
Derivative [Line Items]
Derivative Treatment Date	Feb. 27, 2019
Maturity Date	Aug. 27, 2020
Original Principal Note Amount	$ 51,500
Issuances	75,013
Mark-to-Market	3,962
Derivative Valuation	$ 78,975
8% Convertible Notes Payable- issued March 26, 2019 [Member]
Derivative [Line Items]
Derivative Treatment Date	Mar. 26, 2019
Maturity Date	Sep. 21, 2020
Original Principal Note Amount	$ 43,000
Issuances	46,775
Mark-to-Market	3,368
Derivative Valuation	$ 50,143

Derivatives and Fair Value In_4

Derivatives and Fair Value Instruments (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)
Derivatives and Fair Value Instruments (Textual)
Convertible note payable, description	The 5% Convertible Note Payable and the 8% Convertible Notes Payable, the 9% convertible note payable and the 12% convertible notes payable are valued at March 31,2019. The following assumptions were used for the valuation of the embedded derivative: The stock price (prior period reverse split 1,000:1) of $0.0438 increased to $0.1400 then decreased to $0.0622 in this period (basis for the variable conversion prices) would fluctuate with the Company projected volatility.An event of default for the Convertible Note would occur 0% of the time, increasing 1.00% per month to a maximum of 5.0%; Alternative financing for the Convertible Note would be initially available to redeem the note 0% of the time and increase monthly by 1% to a maximum of 10%; Capital raising events (a single financing at 1 month from the valuation date) was previously a factor for the VV Note but are no longer projected. The full reset events projected to occur based on future stock issuance (single event) result in a reset exercise price. The monthly trading volume would average $371,000 (rounded) as of 3/31/19 and would increase at 5% per month; ownership limits conversion across LG's notes based on 4.99% with shares outstanding increasing monthly by 1%. The variable conversion price of 45% to 65% over 3 to 20 trading days would have effective rates of 35.75% to 52.79%; The Note Holders would automatically convert the notes early (and not hold to maturity) with variable conversion prices and full ratchet resets if the registration was effective and not in default; The projected annual volatility for each valuation period was based on the historical volatility of the Company in the range 417% to 296%.
Embedded derivative, description	The Company's 5% convertible notes payable and 8% convertible notes payable and 9% convertible note payable issued to unrelated investors is a hybrid instrument, which warrants separate accounting as a derivative instrument.
Derivatives convertible notes payable, description	the 5% Convertible Notes Payable issued June 12th 2015 and the 8% Convertible Note payable issued June 25th 2015 and for the 8% Convertible Notes Payable issued January 7, 2016 and March 7, 2016, the 9% Convertible Note payable issued October 1, 2016 the 8% Convertible Notes Payable issued January 25, 2018 and June 4, 2018, the 8% convertible notes payable issued October 1, 2018 and November 19, 2018, the 8% convertible notes payable issued February 20, 2019 and February 27, 2019 and March 26, 2019 and to the 12% convertible notes payable issued January 28, 2019 and February 6, 2019 and February 25, 2019.
Mark-to market fair value adjustment	$ 437,126
Level 3 [Member]
Derivatives and Fair Value Instruments (Textual)
Derivatives convertible notes payable, description	The 5% Convertible Notes Payable issued June 12th 2015 and the 8% Convertible Note payable issued June 25th 2015 and for the 8% Convertible Notes Payable issued January 7, 2016 and March 7, 2016 and May 1, 2017 and June 2, 2017 and July 10, 2017 and August 15, 2017, the 9% Convertible Note payable issued October 1, 2016, The 8% Convertible note payable issued January 25, 2018, the 8% Convertible note payable issued June 4, 2018 and the 8% convertible notes payable issued October 1, 2018 and November 19, 2018, the 8% convertible notes payable issued February 20, 2019 and February 27, 2019 and March 26, 2019 and to the 12% convertible notes payable issued January 28, 2019 and February 6, 2019 and February 25, 2019 for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. We have valued the automatic conditional conversion, re-pricing/down-round, change of control; default and follow-on offering provisions using a lattice model, with the assistance of a valuation consultant, for which management understands the methodologies. These models incorporate transaction details such as Company stock price, contractual terms, maturity, risk free rates, as well as assumptions about future financings, volatility, and holder behavior as of issuance and March 31, 2019. The primary assumptions include: projected annual volatility of 296%-417%; the follow-on securities purchase option; the conversion feature as a percentage of Market; automatic/conditional conversions; market price trigger events.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Series C Preferred Stock [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Expected life	8 months 12 days	8 months 12 days
Risk free interest rate		2.75%
Dividend yield	0.00%	0.00%
Minimum [Member]
Class of Stock [Line Items]
Expected volatility	342.00%	403.00%
Risk free interest rate	2.40%
Maximum [Member]
Class of Stock [Line Items]
Expected volatility	415.00%	435.00%
Risk free interest rate	2.46%

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Oct. 12, 2018	Jul. 23, 2018	Mar. 31, 2019	Dec. 31, 2018	Sep. 19, 2017
Class of Stock [Line Items]
Reverse stock split, description		The Company effected a 1-for-1,000 reverse stock split of its issued and outstanding common stock. The number of shares of common stock issued and outstanding post- reverse stock split is 1,404,073.
Additional paid-in-capital increased				$ 140,169
Common stock, shares authorized			4,000,000,000	4,000,000,000
Common stock, par value			$ 0.0001	$ 0.0001
Common stock, shares outstanding			5,808,883	3,482,840
Common stock, shares issued			5,808,883	3,482,840
Convertible preferred, stock description	The Company filed with the State of Nevada a certificate of designation pursuant to which the Company designated a new class of preferred stock as the Company's Series C Convertible Preferred Stock ("Series C Preferred") having a $100.00 stated value per share ("Stated Value") and a par value equal to $0.0001 per share. The Company designated 5,000 shares of Series C Preferred. Subject to a beneficial ownership limitation equal to 4.99%, each share of Series C Preferred is convertible into 25,000 shares of the Company's common stock.		At December 31, 2016 there were 39,000 shares issued of which 12,900 shares of Series B preferred were converted into common stock in accordance with the terms of the Series B Preferred stock. Therefore; there were 26,100 shares outstanding at December 31, 2016. The Series B preferred stock has no voting rights. During the quarter ended March 31, 2017, 18,100 shares of Series B preferred shares were converted into common stock in accordance with the terms of the Series B preferred stock. As of result there were 8,000 shares of Series B preferred shares outstanding at December 31, 2018. The holders of the Series B convertible preferred stock have the right to convert the same into Common Stock of the Corporation at the ratio of one (1) share of Series B Convertible Preferred for five hundred (500) shares of Common Stock.
Common Stock [Member]
Class of Stock [Line Items]
Common stock, shares authorized					4,000,000,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			5,000	5,000
Preferred stock, par value			$ 0.0001	$ 0.0001
Preferred stock, shares issued			315	177
Preferred stock, shares outstanding			315	177
Common stock stated value				$ 17,700
Preferred shares issued to professionals for their services value			$ 184,506	$ 204,212
Preferred shares issued to professionals for their services			138
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000,000	1,000,000
Preferred stock, par value			$ 0.0001	$ 0.0001
Preferred stock, shares issued			500,000	500,000
Preferred stock, shares outstanding			500,000	500,000
Preferred stock has preferential voting rights			The preferred stock has preferential voting rights of 2,000 votes per outstanding share.
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			50,000	50,000
Preferred stock, par value			$ 0.0001	$ 0.0001
Preferred stock, shares issued			8,000	8,000
Preferred stock, shares outstanding			8,000	8,000

Stockholders' Equity (Details_2

Stockholders' Equity (Details Textual 1) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Stockholders' Equity (Textual)
Issued shares for services	$ 14,127		$ 46,133	$ 20,259	$ 7,202
Common Stock Issuance Activity [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares					18,000
Common Stock Issuance Activity [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share					$ 0.0006
Common Stock Issuance Activity [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share					$ 0.0011
Common Stock Issuance Activity One [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares					376,111
Common Stock Issuance Activity One [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share					$ 0.0004
Common Stock Issuance Activity One [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share					$ 0.0006
Common Stock Issuance Activity Two [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares				67,500
Common Stock Issuance Activity Two [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share				$ 0.0004
Common Stock Issuance Activity Two [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share				$ 0.0004
Common Stock Issuance Activity Three [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares				92,015
Common Stock Issuance Activity Three [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share				$ 0.000174
Common Stock Issuance Activity Three [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share				$ 0.00025
Common Stock Issuance Activity Four [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares			634,053
Common Stock Issuance Activity Four [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share			$ 0.0525
Common Stock Issuance Activity Four [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share			$ 0.18
Common Stock Issuance Activity Five [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares			427,755
Common Stock Issuance Activity Five [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share			$ 0.0190
Common Stock Issuance Activity Five [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share			$ 0.1173
Common Stock Issuance Activity Six [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares		1,017,959
Common Stock Issuance Activity Six [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share		$ 0.019
Common Stock Issuance Activity Six [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share		$ 0.025
Common Stock Issuance Activity Seven [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares	277,000
Price per share	$ 0.051
Common Stock Issuance Activity Eight [Member]
Stockholders' Equity (Textual)
Issued shares for services, shares	2,049,043
Common Stock Issuance Activity Eight [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Price per share	$ 0.015
Common Stock Issuance Activity Eight [Member] | Maximum [Member]
Stockholders' Equity (Textual)
Price per share	$ 0.029
Series C Preferred Stock [Member]
Stockholders' Equity (Textual)
Preferred stock, shares issued	315	177
Preferred stock, shares outstanding	315	177
Preferred stock stated value	$ 31,500
Preferred stock, par value	$ 0.0001	$ 0.0001

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 18,600
2020	24,600
2021	$ 4,100

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Lease Cost:
Operating lease cost	$ 3,188
Other Lease Information:
Cash paid for amounts in lease liabilities	4,650
Operating cash flows from operating leases	4,650
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 41,382
Weighted-average remaining lease term-operating leases	1 year 11 months 1 day
Weighted-average discount rate--operating leases	8.00%

Commitments and Contingencies_4

Commitments and Contingencies (Details Textual) - USD ($)	Sep. 12, 2016	Jul. 31, 2017	Mar. 31, 2019	Mar. 31, 2018
Commitments and Contingencies (Textual)
Rents offices per month amount			$ 1,575	$ 1,575
Commitments, description		The Company leased additional space at this location thereby increasing the monthly rent to $1,550.	The Company also has ready-to-go office space available to be used for meetings etc. at a nominal cost of approximately $100 per month with no commitment.
Cost of space			$ 300	300
Total rent expense				5,822
Lease agreement, description			A new lease was signed in March 2018 for the same space with the rent increasing to $2,050 effective January 1, 2020 (after negotiation with the landlord). The Company has no finance leases.
Office premises cost	$ 650
Office premises cost term	1 year
Net operating lease assets			$ 41,382
Net operating lease liabilities			43,326
Stockholder [Member]
Commitments and Contingencies (Textual)
Rents offices per month amount			$ 525	$ 525
Dr. Gupta Pharma LLC [Member]
Commitments and Contingencies (Textual)
Distribution agreement description			The Company, via its subsidiary USA Pharma, has exclusive New Jersey distribution rights for all CBD products and non-exclusive rights to all other territories. The agreement is for a term of 3 years, but parties have the right to terminate. Upon agreement signing, 120 shares of Series C Convertible Preferred stock was issued by the Company to Dr. Gupta. Dr. Gupta shall have 30% of the issued and outstanding common stock of the Company during the term of this agreement. Should the percentage of ownership drop below 30% then the Company must issue additional Series C Convertible Preferred Shares which are convertible into the required additional amount of common stock minus 3,000,000 shares of common stock.
Dr. Ronald L. Rubin [Member]
Commitments and Contingencies (Textual)
Distribution agreement description			20% for direct sales 5% for any sale that he oversees that involves another sales person 5% for any sales related to a distribution agreement. He is to be issued 1 Series C Preferred share or 25,000 common shares per month

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Related Party Transactions [Abstract]
Due to Related Party	$ 8,921	$ 8,921
Due to officer/stockholder	8,955	8,955
Due to other stockholders	1,100	3,100
Total Related Party Obligations	$ 18,976	$ 20,976

Related Party Transactions (D_2

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended					12 Months Ended
	Sep. 25, 2017	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2018	Dec. 31, 2015	Dec. 31, 2014
Related Party Transactions (Textual)
Current base compensation		$ 37,500		$ 37,500
Converted into shares of common stock		49,753,279
Convertible notes payable to investor		$ 1,290,863
Conversion of stock, shares		49,753,279
Accrued expenses - officer's compensation		$ 403,186					$ 388,981
Related-party noteholder, description			The original related-party noteholder sold $20,000 in principal on this note to an unrelated third party investor thereby leaving $80,250 in principal balance due to the related party original noteholder and $20,000 in principal due to the unrelated third-party investor.
Convertible notes payable		588,092					522,446
Cash paydowns to noteholder in total amount		5,700					$ 32,550
Promissory Note [Member]
Related Party Transactions (Textual)
Accrued interest		$ 18,986
Common stock issued on fully satisfied issuance		17,273
Convertible notes payable to investor	$ 16,250			$ 15,000
Conversion of stock, shares	25,000			60,000
Series B Preferred Stock [Member]
Related Party Transactions (Textual)
Issuance of common shares upon conversion of shares					18,100	3,400
Converted into shares of common stock					9,050	1,700
Accrued interest		$ 150,000
Convertible notes payable to investor		$ 150,000
Conversion of stock, shares		25,000
Common Stock [Member]
Related Party Transactions (Textual)
Conversion of stock, shares			30,000
Principal outstanding balance			$ 7,500
Common Stock [Member] | Promissory Note [Member]
Related Party Transactions (Textual)
Conversion of stock, shares							120,000
Convertible notes payable converted into common stock		200,000					495,000
Sale of convertible redeemable principal amount		$ 16,650					$ 16,650
Convertible notes payable							3,350
Principal amount converted		3,800					30,195
Principal outstanding balance		41,505					$ 51,005
Chief Executive Officer [Member]
Related Party Transactions (Textual)
Current base compensation		$ 150,000						$ 100,000	$ 100,000

Basis of Reporting - Going Co_2

Basis of Reporting - Going Concern (Details)	Mar. 31, 2019USD ($)
Basis of Reporting - Going Concern (Textual)
Net operating loss carryforward	$ 5,542,067

Stock Compensation - Equity I_2

Stock Compensation - Equity Incentive Plan (Details) - shares	Dec. 06, 2016	Jan. 31, 2018	May 31, 2017	Jul. 31, 2016	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
2016 Equity Incentive Plan [Member]
Stock Compensation - Equity Incentive Plan (Textual)
Aggregate of shares of common stock				20,000,000
Common stock to non-employees for services rendered										27,100
Issuance of common shares	32,000									0
2017 Equity Incentive Plan [Member]
Stock Compensation - Equity Incentive Plan (Textual)
Aggregate of shares of common stock			125,000
Common stock to non-employees for services rendered											108,000
Issuance of common shares											17,000
2018 Equity Incentive Plan [Member]
Stock Compensation - Equity Incentive Plan (Textual)
Aggregate of shares of common stock		175,000
Common stock to non-employees for services rendered								17,500	4,000
Issuance of common shares						170,500	170,500	170,500	188,000
2019 Equity Incentive Plan [Member]
Stock Compensation - Equity Incentive Plan (Textual)
Common stock to non-employees for services rendered					277,000
Issuance of common shares					4,723
Common stock purchase, description					The total number of shares of Common Stock which may be purchased or granted directly by Options, Stock Awards or Restricted Stock Purchase Offers, or purchased indirectly through exercise of Options granted under the Plan shall not exceed 5,000,000 shares.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Apr. 26, 2019	Mar. 31, 2019	Dec. 31, 2018
Subsequent Events (Textual)
Converted into shares of common stock		49,753,279
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Subsequent Events (Textual)
Issue a convertible promissory note	$ 58,000
Note pays interest rate	8.00%
Date of maturity	Oct. 20, 2020
Series C Preferred Stock [Member]
Subsequent Events (Textual)
Converted into shares of common stock		150,000
Convertible Preferred shareholder converted shares		6
Convertible Promissory Notes [Member]
Subsequent Events (Textual)
Debt conversion convertible shares, subsequent to the year end		3,241,450
Aggregate principal amount, subsequent to the year end		$ 93,415
Accrued interest		$ 8,956
Preferred stock, description			The Company issued an aggregate 1 share of Series C Convertible Preferred Stock to a consultant for services performed. This 1 share of Series C Convertible Preferred Stock are convertible into 25,000 shares of common stock of the Company. The 1 share of Series C Convertible Preferred Stock will be recorded on the Company's books at fair value using a Black-Scholes pricing model.